| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts Index
|
|
|
2006
|
9 |
6 |
p. A401-A409
nvt p.
|
artikel
|
| 2 |
Abstracts Index
|
|
|
2006
|
9 |
6 |
p. A401-A409
|
artikel
|
| 3 |
CN4 COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NONSMALL CELL LUNG CANCER (NSCLC) IN THE UK
|
Lewis, G
|
|
2006
|
9 |
6 |
p. A203-A204
nvt p.
|
artikel
|
| 4 |
CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION
|
Pompen, M
|
|
2006
|
9 |
6 |
p. A203-
1 p.
|
artikel
|
| 5 |
CN1 TREATMENTS FOR METASTATIC MELANOMA: SYNTHESIS OF EVIDENCE FROM RANDOMIZED TRIALS
|
Einarson, TR
|
|
2006
|
9 |
6 |
p. A202-A203
nvt p.
|
artikel
|
| 6 |
CN2 USING PSYCHOMETRIC AND CLINIMETRIC TECHNIQUES TO SELECT ITEMS FOR USE IN A NEW INSTRUMENT TO MEASURE CANCER-RELATED FATIGUE
|
Baro, E
|
|
2006
|
9 |
6 |
p. A203-
1 p.
|
artikel
|
| 7 |
Contributed Podium Presentations
|
|
|
2006
|
9 |
6 |
p. A187-A207
|
artikel
|
| 8 |
Contributed Poster Presentations
|
|
|
2006
|
9 |
6 |
p. A208-A393
|
artikel
|
| 9 |
CV4 ASSESSING COST-EFFECTIVENESS BEFORE MARKETING: A CASE-STUDY OF RIMONABANT FOR REDUCTION OF CARDIOMETABOLIC RISK IN PATIENTS WITH DYSLIPIDEMIA IN THE UK
|
Caro, JJ
|
|
2006
|
9 |
6 |
p. A193-
1 p.
|
artikel
|
| 10 |
CV1 COST-EFFECTIVENESS OF EPTIFIBATIDE IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN GERMANY
|
Dewilde, S
|
|
2006
|
9 |
6 |
p. A192-
1 p.
|
artikel
|
| 11 |
CV3 COST-EFFECTIVENESSS OF INTENSIVE STATIN THERAPY COMPARED TO MODERATE STATIN THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: ANALYSIS FROM CANADA, GERMANY AND THE UK
|
Drummond, MF
|
|
2006
|
9 |
6 |
p. A193-
1 p.
|
artikel
|
| 12 |
CV6 DIFFERENCES IN PERCENTAGE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) REDUCTION AND GOAL ATTAINMENT AMONG NEWLY INITIATED USERS OF STATINS IN A REAL LIFE SETTING
|
Heintjes, E
|
|
2006
|
9 |
6 |
p. A197-A198
nvt p.
|
artikel
|
| 13 |
CV5 PHARMACOECONOMIC EVALUATION OF SIMVASTATIN VERSUS “NO TREATMENT” IN PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE (CHD) IN POLAND
|
Plich, A
|
|
2006
|
9 |
6 |
p. A197-
1 p.
|
artikel
|
| 14 |
CV8 REAL WORLD MORTALITY OF THE HYPERTENSIVE PATIENT AS DEFINED IN THE ASCOT-LLA
|
F Bobadilla, J
|
|
2006
|
9 |
6 |
p. A198-
1 p.
|
artikel
|
| 15 |
CV2 RECURRENT INFREQUENT UNEXPLAINED PALPITATIONS (RUP) STUDY: COMPARISON OF IMPLANTABLE LOOP RECORDER VERSUS CONVENTIONAL DIAGNOSTIC TESTING
|
Giada, F
|
|
2006
|
9 |
6 |
p. A192-
1 p.
|
artikel
|
| 16 |
CV7 RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITAL INPATIENT ADMISSION FOR CONGESTIVE HEART FAILURE
|
Gemmen, EK
|
|
2006
|
9 |
6 |
p. A198-
1 p.
|
artikel
|
| 17 |
DB3 GLYCEMIC RESPONSE TO NEWLY INITIATED ANTIHYPERGLYCEMIC THERAPIES IN A LARGE MANAGED CARE ORGANIZATION
|
Karter, AJ
|
|
2006
|
9 |
6 |
p. A187-A188
nvt p.
|
artikel
|
| 18 |
DB2 INSULIN THERAPY AMONG TYPE 2 DIABETES PATIENTS: IMPACT OF CONVERSION TO A PEN DEVICE ON ADHERENCE, HYPOGLYCEMIC EVENTS, AND COSTS
|
Lee, WC
|
|
2006
|
9 |
6 |
p. A187-
1 p.
|
artikel
|
| 19 |
DB1 RATES AND RISKS OF STARTING INSULIN IN DIABETES MELLITUS TYPE-2 PATIENTS
|
Sturkenboom, MC
|
|
2006
|
9 |
6 |
p. A187-
1 p.
|
artikel
|
| 20 |
DB4 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES: COST UTILITY ANALYSIS IN A UNITED STATES THIRD-PARTY PAYER SETTING
|
Palmer, AJ
|
|
2006
|
9 |
6 |
p. A188-
1 p.
|
artikel
|
| 21 |
DISCLOSURE INFORMATION
|
|
|
2006
|
9 |
6 |
p. A394-A400
nvt p.
|
artikel
|
| 22 |
DISCLOSURE INFORMATION
|
|
|
2006
|
9 |
6 |
p. A394-A400
|
artikel
|
| 23 |
ERRATUM
|
|
|
2006
|
9 |
6 |
p. A410-
1 p.
|
artikel
|
| 24 |
ERRATUM
|
|
|
2006
|
9 |
6 |
p. A410
|
artikel
|
| 25 |
ES1 COST-UTILITY ANALYSES OF NEW MEDICAL TECHNOLOGIES: OFTEN COST-EFFECTIVE, SOMETIMES COST-INEFFECTIVE, DOMINANT, OR DOMINATED, BUT ALMOST NEVER ‘DECREMENTALLY’ COST-EFFECTIVE
|
Kent, DM
|
|
2006
|
9 |
6 |
p. A188-
1 p.
|
artikel
|
| 26 |
ES2 DIRECT MEDICAL COSTS OF SOLID ORGAN TRANSPLANT IN BRITISH COLUMBIA, CANADA
|
Levy, AR
|
|
2006
|
9 |
6 |
p. A188-A189
nvt p.
|
artikel
|
| 27 |
ES7 DIRECT MEDICAL COSTS OF STROKE ACCORDING TO HANDICAP LEVELS AFTER 12 AND 18 MONTHS
|
Bouchez, M
|
|
2006
|
9 |
6 |
p. A199-
1 p.
|
artikel
|
| 28 |
ES6 ENTRY AND PRICE RESPONSE IN MARKETS WITHOUT PATENT PROTECTION:THE CASE OF PHARMACEUTICALS IN ARGENTINA
|
Maceira, DA
|
|
2006
|
9 |
6 |
p. A199-
1 p.
|
artikel
|
| 29 |
ES3 PROCESS OPTIMIZATION IN A 10-BED INTENSIVE CARE UNIT (ICU) IN GERMANY: IMPACT ON CASE-RELATED TREATMENT COSTS
|
Brecht, JG
|
|
2006
|
9 |
6 |
p. A189-
1 p.
|
artikel
|
| 30 |
ES5 RIMONABANT FOR THE TREATMENT OF OVERWEIGHT AND OBESE INDIVIDUALS AT INCREASED CARDIOMETABOLIC RISK:AN ECONOMIC EVALUATION USING DISCRETE EVENT SIMULATION
|
Getsios, D
|
|
2006
|
9 |
6 |
p. A198-A199
nvt p.
|
artikel
|
| 31 |
ES4 SYSTEMATIC REVIEW OF BUDGET IMPACT ANALYSES
|
Muszbek, N
|
|
2006
|
9 |
6 |
p. A189-
1 p.
|
artikel
|
| 32 |
Estimating the Cost-Effectiveness of Quality-Improving Interventions in Oral Anticoagulation Management within General Practice
|
Claes, Neree
|
|
2006
|
9 |
6 |
p. 369-376
8 p.
|
artikel
|
| 33 |
Estimating the Cost-Effectiveness of Quality-Improving Interventions in Oral Anticoagulation Management within General Practice
|
Claes, Neree
|
|
2006
|
9 |
6 |
p. 369-376
|
artikel
|
| 34 |
ES8 TREATMENT COSTS OF DIFFERENT PHASES IN BREAST CANCER (BC) IN HUNGARY
|
Muszbek, N
|
|
2006
|
9 |
6 |
p. A199-A200
nvt p.
|
artikel
|
| 35 |
GI4 COST-EFFECTIVENESS OF TRIPLE THERAPIES OF ESOMEPRAZOLE AND RABEPRAZOLE FOR H. PYLORI ERADICATION IN THE PUBLIC SECTOR OF HONG KONG
|
Lee, KK
|
|
2006
|
9 |
6 |
p. A190-A191
nvt p.
|
artikel
|
| 36 |
GI1 COST OF FUNCTIONAL DYSPEPSIA-RESULTS FROM A LARGE US EMPLOYER DATABASE
|
George, S
|
|
2006
|
9 |
6 |
p. A189-A190
nvt p.
|
artikel
|
| 37 |
GI3 COST-UTILITY ANALYSIS IN A UK SETTING OF VASOACTIVE DRUG TREATMENTS IN ACUTE BLEEDING OESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS-A DISCRETE EVENT SIMULATION MODEL
|
Wechowski, JG
|
|
2006
|
9 |
6 |
p. A190-
1 p.
|
artikel
|
| 38 |
GI2 DICLOFENAC-ASSOCIATED ULCER RISK IS REDUCED BY PROTON PUMP INHIBITORS: NESTED CASE CONTROL STUDY
|
Höer, A
|
|
2006
|
9 |
6 |
p. A190-
1 p.
|
artikel
|
| 39 |
HP1 CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS OF CHOLESTEROL LOWERING DRUGS:A SYSTEMATIC REVIEW
|
Gumbs, PD
|
|
2006
|
9 |
6 |
p. A204-
1 p.
|
artikel
|
| 40 |
HP4 SUMMARIZING POPULATION HEALTH USING EQ-5D
|
Chuang, LH
|
|
2006
|
9 |
6 |
p. A205-
1 p.
|
artikel
|
| 41 |
HP3 THE ROLE OF GENERAL PRACTITIONERS IN THE INITIAL MANAGEMENT OF WOMEN WITH URINARY INCONTINENCE IN FRANCE, GERMANY, SPAIN AND THE UK
|
O' Donnell, M
|
|
2006
|
9 |
6 |
p. A204-A205
nvt p.
|
artikel
|
| 42 |
HP2 TRENDS IN ANGIOTENSIN II RECEPTOR BLOCKER (ARB) PRESCRIBING AMONG GENERAL PRACTITIONERS IN THE UK
|
Blak, BT
|
|
2006
|
9 |
6 |
p. A204-
1 p.
|
artikel
|
| 43 |
IH3 FEASIBILITY AND PRIMARY VALIDITY OF A GERMAN EQ-5D CHILDREN'S VERSION
|
Greiner, W
|
|
2006
|
9 |
6 |
p. A191-
1 p.
|
artikel
|
| 44 |
IH2 HEALTH OUTCOMES FOR MOTHERS OF DISABLED AND CHRONICALLY ILL CHILDREN
|
Lethbridge, L
|
|
2006
|
9 |
6 |
p. A191-
1 p.
|
artikel
|
| 45 |
IH4 METHYLPHENIDATE PRESCRIPTIONS FOR CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): NEW DATA FROM NORDBADEN/GERMANY
|
Schlander, M
|
|
2006
|
9 |
6 |
p. A191-A192
nvt p.
|
artikel
|
| 46 |
IH1 PATIENTS' WILLINGNESS TO PAY FOR DIFFERENT CHARACTERISTICS OF THE ATOPIC DERMATITIS TREATMENT
|
Monzini, MS
|
|
2006
|
9 |
6 |
p. A191-
1 p.
|
artikel
|
| 47 |
Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and without Cardiovascular Risk
|
Thiebaud, Patrick
|
|
2006
|
9 |
6 |
p. 361-368
8 p.
|
artikel
|
| 48 |
Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and without Cardiovascular Risk
|
Thiebaud, Patrick
|
|
2006
|
9 |
6 |
p. 361-368
|
artikel
|
| 49 |
IN1 BUDGETARY IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINATION OF NEWBORNS IN THE PERSPECTIVE OF THE REGIONAL HEALTH CARE SYSTEM OF LOMBARDY
|
Berto, P
|
|
2006
|
9 |
6 |
p. A205-
1 p.
|
artikel
|
| 50 |
IN2 EUROPEAN SURVEILLANCE OF ANTIMICROBIAL CONSUMPTION (ESAC): DEVELOPING VALID ANTIBIOTIC PRESCRIBING QUALITY INDICATORS FOR AMBULATORY CARE
|
Ferech, M
|
|
2006
|
9 |
6 |
p. A205-A206
nvt p.
|
artikel
|
| 51 |
IN4 MEDICAL MANAGEMENT AND COSTS ASSOCIATED WITH STAPHYLOCOCCUS AUREUS (SA) BACTERAEMIA IN HAEMODIALYSIS PATIENTS:A COST-OF-ILLNESS STUDY
|
Strens, D
|
|
2006
|
9 |
6 |
p. A206-
1 p.
|
artikel
|
| 52 |
IN3 RELATIONSHIP BETWEEN ADHERENCE TO ANTIRETROVIRAL THERAPY AND THE COST-EFFECTIVENESS OF ANTIRETROVIRAL THERAPY
|
Habib, MJ
|
|
2006
|
9 |
6 |
p. A206-
1 p.
|
artikel
|
| 53 |
Integrating the Patient's Perspective into Device Evaluation Trials
|
Leidy, Nancy Kline
|
|
2006
|
9 |
6 |
p. 394-401
8 p.
|
artikel
|
| 54 |
Integrating the Patient’s Perspective into Device Evaluation Trials
|
Leidy, Nancy Kline
|
|
2006
|
9 |
6 |
p. 394-401
|
artikel
|
| 55 |
Longitudinal Metric Properties of Disability Rating Scales for Parkinson's Disease
|
Martinez-Martin, Pablo
|
|
2006
|
9 |
6 |
p. 386-393
8 p.
|
artikel
|
| 56 |
Longitudinal Metric Properties of Disability Rating Scales for Parkinson’s Disease
|
Martinez-Martin, Pablo
|
|
2006
|
9 |
6 |
p. 386-393
|
artikel
|
| 57 |
MC4 BREAKING THE SILENCE: THE EFFECTS OF EXPLICIT INSTRUCTIONS ON INCORPORATING INCOME IN TTO EXCERCISES
|
Krol, M
|
|
2006
|
9 |
6 |
p. A194-A195
nvt p.
|
artikel
|
| 58 |
MC2 15DS-A NEW DYNAMIC QUALITY OF LIFE TOOL WITH INCREASED SENSITIVITY AND IMPROVED COMPOSITE STRUCTURE FOR RECALL BIAS AND RESPONSE SIFT ADJUSTMENTS
|
Soini, EJ
|
|
2006
|
9 |
6 |
p. A194-
1 p.
|
artikel
|
| 59 |
MC1 GROWTH, CHARACTERISTICS, AND QUALITY OF THE COSTUTILITY LITERATURE THROUGH 2003
|
Palmer, JA
|
|
2006
|
9 |
6 |
p. A193-A194
nvt p.
|
artikel
|
| 60 |
MC6 HOW DO THE SCORES OF GENERIC HRQOL INSTRUMENTS REFLECT THE DIRECT TTO VALUATIONS OF OWN HEALTH BY GENERAL POPULATION?
|
Kotomäki, T
|
|
2006
|
9 |
6 |
p. A207-
1 p.
|
artikel
|
| 61 |
MC5 HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS: RESULTS FOR GERMANY FROM A MULTI-COUNTRY CROSSSECTIONAL STUDY
|
Zlateva, G
|
|
2006
|
9 |
6 |
p. A206-A207
nvt p.
|
artikel
|
| 62 |
MC8 THE COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS:ACCOUNTING FOR MEDICAL COSTS IN LONGER LIFE EXPECTANCIES
|
Feenstra, TL
|
|
2006
|
9 |
6 |
p. A207-
1 p.
|
artikel
|
| 63 |
MC7 TRANSLATION AND VALIDATION OF NEW LANGUAGE VERSIONS OF THE ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) QUESTIONNAIRE
|
Doward, LC
|
|
2006
|
9 |
6 |
p. A207-
1 p.
|
artikel
|
| 64 |
MC3 USING SIMULATIONS TO EXPLORE THE INFLUENCE OF COMPETING RISK ON TREATMENT-EFFECT
|
Kent, DM
|
|
2006
|
9 |
6 |
p. A194-
1 p.
|
artikel
|
| 65 |
OA4 A HEALTH-ECONOMIC EVALUATION OF RHBMP-2 IN SPINE FUSION SURGERY IN GERMANY AND UK
|
Chhabra, A
|
|
2006
|
9 |
6 |
p. A201-
1 p.
|
artikel
|
| 66 |
OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)
|
Le Pen, C
|
|
2006
|
9 |
6 |
p. A200-A201
nvt p.
|
artikel
|
| 67 |
OA1 QUALITY OF LIFE IN EARLY RHEUMATOID ARTHRITIS TREATED WITH COMBINATION VS. SINGLE DRUG THERAPY-RESULTS FROM FIN-RACO TRIAL
|
Hahl, J
|
|
2006
|
9 |
6 |
p. A200-
1 p.
|
artikel
|
| 68 |
OA2 SCREENING FOR PATIENTS AT RISK FOR OSTEOPOROSIS BASED ON A RISK-QUESTIONNAIRE IN A GERMAN SETTING OF COMMUNITY PHARMACIES
|
Lyssy, AE
|
|
2006
|
9 |
6 |
p. A200-
1 p.
|
artikel
|
| 69 |
PAA8 A COMPARISON OF CLAIMS RATIO BETWEEN PRIMARY AND SECONDARY DRUGS IN THE MANAGEMENT OF ASTHMA. A CANADIAN ANALYSIS
|
Ciobanu, A
|
|
2006
|
9 |
6 |
p. A334-
1 p.
|
artikel
|
| 70 |
PAA7 ANALYZING THE INFLUENCE OF SWITCHING BETWEEN DIFFERENT ASTHMA REGIMES ON MEDICATION ADHERENCE TO ASTHMA THERAPY, RESOURCE UTILIZATION AND COSTS
|
Buesch, K
|
|
2006
|
9 |
6 |
p. A334-
1 p.
|
artikel
|
| 71 |
PAA1 CLINICAL EFFECTIVENESS OF ADJUSTABLE DOSING SINGLE INHALER BUDESONIDE/FORMOTEROL FOR ASTHMA AND BUDGET IMPACT ANALYSIS
|
Kaczor, M
|
|
2006
|
9 |
6 |
p. A332-
1 p.
|
artikel
|
| 72 |
PAA11 COST-EFFECTIVENESS ANALYSIS FOR THE ASSESSMENT OF PREVENTIVE SCHEMES BASED ON GENETIC SCREENING
|
Gutierrez de Mesa, E
|
|
2006
|
9 |
6 |
p. A335-
1 p.
|
artikel
|
| 73 |
PAA3 COST OF MANAGING ASTHMA EXACERBATIONS WITH STABLE DOSING OF SALMETEROL/FLUTICASONE COMBINED PRODUCT (SFC) COMPARED WITH ADJUSTABLE MAINTENANCE DOSING (AMD) OF FORMOTEROL/BUDESONIDE COMBINED PRODUCT (FBC) IN POLAND
|
Orlewska, E
|
|
2006
|
9 |
6 |
p. A333-
1 p.
|
artikel
|
| 74 |
PAA5 ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN GERMANY
|
Berg, J
|
|
2006
|
9 |
6 |
p. A333-
1 p.
|
artikel
|
| 75 |
PAA2 EFFECT OF SUBLINGUAL IMMUNOTHERAPY (SLIT) ON DIRECT MEDICAL COSTS FOR PATIENTS WITH ALLERGIC RHINITIS AND ASTHMA: RESULTS FROM THE SIMAP DATABASE STUDY
|
Berto, P
|
|
2006
|
9 |
6 |
p. A332-A333
nvt p.
|
artikel
|
| 76 |
PAA10 HEALTH PLAN STRUCTURE AND EXPENDITURES FOR ASTHMA CARE
|
Nurmagambetov, T
|
|
2006
|
9 |
6 |
p. A335-
1 p.
|
artikel
|
| 77 |
PAA13 OBTAINING POPULATION REFERENCE VALUES FOR THE ESPRINT-15 QUESTIONNAIRE, A SPECIFIC QUALITY OF LIFE SCALE FOR ALLERGIC RHINITIS (AR)
|
Valero, A
|
|
2006
|
9 |
6 |
p. A336-
1 p.
|
artikel
|
| 78 |
PAA14 PATIENT-PERCEIVED SIDE EFFECTS OF CICLESONIDE AS COMPARED TO FLUTICASONE PROPIONATE IN THE TREATMENT OF MODERATE ASTHMA USING THE INHALED CORTICOSTEROID QUESTIONNAIRE
|
van der Molen, T
|
|
2006
|
9 |
6 |
p. A336-
1 p.
|
artikel
|
| 79 |
PAA4 PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA PATIENTS
|
Kulikov, A
|
|
2006
|
9 |
6 |
p. A333-
1 p.
|
artikel
|
| 80 |
PAA15 THE CONSTRUCT VALIDITY AND TEST-RETEST RELIABILITY OF THE INHALED CORTICOSTEROID QUESTIONNAIRE (ICQ): A PATIENT SELF-REPORTED SIDE EFFECT SCALE
|
Foster, JM
|
|
2006
|
9 |
6 |
p. A336-A337
nvt p.
|
artikel
|
| 81 |
PAA12 THE EFFECT OF SWITCHING ON ADHERENCE TO DIFFERENT TYPES OF ASTHMA TREATMENT
|
Buesch, K
|
|
2006
|
9 |
6 |
p. A335-A336
nvt p.
|
artikel
|
| 82 |
PAA9 THE EFFECTS OF GENERIC-ONLY DRUG COVERAGE ON INHALED CORTICOSTEROID EXPENDITURES AND USE
|
Fung, V
|
|
2006
|
9 |
6 |
p. A334-A335
nvt p.
|
artikel
|
| 83 |
PAA6 VALUING REDUCED RATES OF OROPHARYNGEAL ADVERSE EVENTS: COMPARISON OF CICLESONIDE WITH FLUTICASONE PROPIONATE
|
Wlodarczyk, JH
|
|
2006
|
9 |
6 |
p. A334-
1 p.
|
artikel
|
| 84 |
PAR3 AN ECONOMIC EVALUATION OF THE USE OF EXOGEN FOR FRESH AND NON-UNION FRACTURES OF THE TIBIA IN THE UK
|
Taylor, MJ
|
|
2006
|
9 |
6 |
p. A221-
1 p.
|
artikel
|
| 85 |
PAR11 ARE THEY MEASURABLE? A STUDY ON ELICITING INDIRECT AND INTANGIBLE COSTS OF KNEE OSTEOARTHRITIS USING HUMAN CAPITAL APPROACH AND WILLINGNESS-TO-PAY IN MULTIETHNIC ASIAN POPULATION IN SINGAPORE
|
Xie, F
|
|
2006
|
9 |
6 |
p. A223-
1 p.
|
artikel
|
| 86 |
PAR9 CO-PRESCRIPTION OF GASTROPROTECTIVE AGENTS FOR PATIENTS AT RISK OF NSNSAID-INDUCED GASTROINTESTINAL HARM
|
Lister, S
|
|
2006
|
9 |
6 |
p. A223-
1 p.
|
artikel
|
| 87 |
PAR1 COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT VS INFLIXIMAB FOR TREATMENT OF SEVERE RHEUMATOID ARTHRITIS IN BRAZIL
|
Saggia, MG
|
|
2006
|
9 |
6 |
p. A220-
1 p.
|
artikel
|
| 88 |
PAR6 COST-UTILITY ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS PATIENTS IN CANADA
|
Mistry, B
|
|
2006
|
9 |
6 |
p. A222-
1 p.
|
artikel
|
| 89 |
PAR7 DIFFUSION OF HEALTH TECHNOLOGIES IN DENMARK- LAGGARDS OR EARLY ADOPTERS?-FOUR CASE-STUDIES REGARDING DRIVERS AND BARRIERS
|
Poulsen, PB
|
|
2006
|
9 |
6 |
p. A222-
1 p.
|
artikel
|
| 90 |
PAR4 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH BLUNT AND PENETRATING TRAUMA IN A UNITED STATES MANAGED CARE POPULATION
|
Candrilli, SD
|
|
2006
|
9 |
6 |
p. A221-
1 p.
|
artikel
|
| 91 |
PAR5 MODELING THE ECONOMIC AND HEALTH CONSEQUENCES OF MANAGING CHRONIC OSTEOARTHRITIS PAIN WITH ORAL OPIOIDS IN GERMANY
|
Ward, A
|
|
2006
|
9 |
6 |
p. A221-
1 p.
|
artikel
|
| 92 |
PAR10 THE COST-UTILITY OF ADALIMUMAB (HUMIRA®) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN DENMARK
|
Aagren, M
|
|
2006
|
9 |
6 |
p. A223-
1 p.
|
artikel
|
| 93 |
PAR8 TRENDS IN PRESCRIPTION CLAIMS FOLLOWING THE WITHDRAWAL OF ROFECOXIB FROM THE CANADIAN MARKET
|
Desjardins, O
|
|
2006
|
9 |
6 |
p. A222-
1 p.
|
artikel
|
| 94 |
PAR2 ZOLEDRONIC ACID IN THE LONG-TERM MANAGEMENT OF PAGET'S DISEASE OF THE BONE IN GERMANY-A COSTSAVING APPROACH?
|
Kurth, AA
|
|
2006
|
9 |
6 |
p. A220-
1 p.
|
artikel
|
| 95 |
PCN4 A COMPARATIVE BUDGET IMPACT (BI) ANALYSIS OF ARANESP® (DARBEPOETIN ALFA) 500 mGQ3W VERSUS OTHER ERYTHROPOIESIS STIMULATING PROTEINS (ESP) IN CHEMOTHERAPY-INDUCED ANEMIA (CIA) IN SPAIN
|
Pérez Alcăntara, F
|
|
2006
|
9 |
6 |
p. A276-A277
nvt p.
|
artikel
|
| 96 |
PCN72 A COMPARISON OF PATIENT REPORTED OUTCOMES ACROSS CURATIVE TREATMENTS OF ELDERLY PROSTATE CANCER PATIENTS
|
Jayadevappa, R
|
|
2006
|
9 |
6 |
p. A297-A298
nvt p.
|
artikel
|
| 97 |
PCN33 A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA (QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA):A RETROSPECTIVE STUDY
|
Van Bellinghen, LA
|
|
2006
|
9 |
6 |
p. A286-
1 p.
|
artikel
|
| 98 |
PCN31 A COST MINIMISATION ANALYSIS OF NAVELBINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN IN ADVANCED NONSMALL CELL LUNG CANCER IN POLAND
|
Skowron, A
|
|
2006
|
9 |
6 |
p. A285-
1 p.
|
artikel
|
| 99 |
PCN23 ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL)
|
Hieke, K
|
|
2006
|
9 |
6 |
p. A282-A283
nvt p.
|
artikel
|
| 100 |
PCN66 ADHERENCE IN CANCER PATIENTS RECEIVING ORAL CAPECITABINE
|
Roth, S
|
|
2006
|
9 |
6 |
p. A295-A296
nvt p.
|
artikel
|
| 101 |
PCN63 ADVANCED CUTANEOUS MALIGNANT MELANOMA: SYSTEMATIC REVIEW OF PHARMACOECONOMIC AND QUALITY OF LIFE STUDIES
|
Machado, M
|
|
2006
|
9 |
6 |
p. A295-
1 p.
|
artikel
|
| 102 |
PCN53 AGE-GROUP SPECIFIC COVERAGE OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME
|
Boncz, I
|
|
2006
|
9 |
6 |
p. A292-
1 p.
|
artikel
|
| 103 |
PCN48 A MODEL FOR PROJECTING BOWEL CANCER INCIDENCE AND MORTALITY: APPLICATION TO THE UK BOWEL CANCER SCREENING PROGRAM
|
Muston, D
|
|
2006
|
9 |
6 |
p. A290-
1 p.
|
artikel
|
| 104 |
PCN18 A SENSITIVITY ANALYSIS OF THE COST PER QUALITY ADJUSTED LIFE YEAR (QALY) OF TRASTUZUMAB IN THE TREATMENT OF EARLY BREAST CANCER (EBC)
|
Geary, U
|
|
2006
|
9 |
6 |
p. A281-
1 p.
|
artikel
|
| 105 |
PCN60 ASSESSMENT OF THE COMPUTATIONAL INTELLIGENCE BASED MODELS USEFULNESS FOR PHARMACOECONOMICS NEEDS
|
Polak, S
|
|
2006
|
9 |
6 |
p. A294-
1 p.
|
artikel
|
| 106 |
PCN50 BOWEL CANCER SCREENING. BALANCING COSTEFFECTIVENESS AND AFFORDABILITY
|
Howard, PA
|
|
2006
|
9 |
6 |
p. A291-
1 p.
|
artikel
|
| 107 |
PCN36 BURDEN OF CERVICAL CANCER IN POLAND
|
Kawalec, P
|
|
2006
|
9 |
6 |
p. A286-A287
nvt p.
|
artikel
|
| 108 |
PCN35 BURDEN OF ILLNESS OF RENAL CELL CARCINOMA IN SPAIN
|
Maroto, P
|
|
2006
|
9 |
6 |
p. A286-
1 p.
|
artikel
|
| 109 |
PCN15 CAPECITABINE VS. BOLUS 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH DUKES' C COLON CANCER: PHARMACOECONOMIC EVALUATION OF X-ACT TRIAL– DATA FROM CZECH PERSPECTIVE
|
Jiraskova, L
|
|
2006
|
9 |
6 |
p. A280-
1 p.
|
artikel
|
| 110 |
PCN37 COMPARING MANAGEMENT PATTERNS AND ASSOCIATED COSTS FOR WOMEN WITH ABNORMAL CERVICAL CYTOLOGY IN 5 DIFFERENT COUNTRIES
|
Rash, B
|
|
2006
|
9 |
6 |
p. A287-
1 p.
|
artikel
|
| 111 |
PCN20 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE COMPARED TO TAMOXIFEN FOR TREATMENT OF EARLY BREAST CANCER IN THE HUNGARIAN HEALTH CARE SETTING
|
Kosa, J
|
|
2006
|
9 |
6 |
p. A281-A282
nvt p.
|
artikel
|
| 112 |
PCN27 COST-EFFECTIVENESS AND COST-UTILITY OF FENTANYL TTS (DUROGESIC® 25, 50) VS. SR/IR ORAL MORPHINES IN THE MANAGEMENT OF CHRONIC CANCER PAIN
|
Estevez-Carrizo, FE
|
|
2006
|
9 |
6 |
p. A284-
1 p.
|
artikel
|
| 113 |
PCN22 COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN SPAIN
|
Brosa, M
|
|
2006
|
9 |
6 |
p. A282-
1 p.
|
artikel
|
| 114 |
PCN45 COST EFFECTIVENESS OF ADDING IMATINIB TO CHEMOTHERAPY IN ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL):AN EXPLORATORY ANALYSIS FOR THE UK
|
Botteman, MF
|
|
2006
|
9 |
6 |
p. A289-
1 p.
|
artikel
|
| 115 |
PCN13 COST-EFFECTIVENESS OF ADJUVANT CAPECITABINE, MAYO CLINIC AND DE GRAMONT REGIMENS FOR STAGE III COLON CANCER IN THE FRENCH SETTING
|
Tilleul, P
|
|
2006
|
9 |
6 |
p. A279-
1 p.
|
artikel
|
| 116 |
PCN43 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN FRANCE
|
Brown, B
|
|
2006
|
9 |
6 |
p. A289-
1 p.
|
artikel
|
| 117 |
PCN19 COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN SPAIN
|
Brosa, M
|
|
2006
|
9 |
6 |
p. A281-
1 p.
|
artikel
|
| 118 |
PCN12 COST EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) IN POLAND
|
Orlewska, E
|
|
2006
|
9 |
6 |
p. A279-
1 p.
|
artikel
|
| 119 |
PCN42 COST EFFECTIVENESS OF FULVESTRANT AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE RESPONSIVE ADVANCED BREAST CANCER
|
Hirsch, MW
|
|
2006
|
9 |
6 |
p. A288-
1 p.
|
artikel
|
| 120 |
PCN17 COST EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM OR FILGRASTIM IN THE MEDICAL TREATMENT OF BREAST CANCER IN ITALY
|
Chiroli, S
|
|
2006
|
9 |
6 |
p. A280-A281
nvt p.
|
artikel
|
| 121 |
PCN40 COST EFFECTIVENESS OF RITUXIMAB PLUS CVP IN PREVIOUSLY UNTREATED INDOLENT NON-HODGKIN'S LYMPHOMA
|
Maturi, B
|
|
2006
|
9 |
6 |
p. A288-
1 p.
|
artikel
|
| 122 |
PCN16 COST-EFFECTIVENESS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE IN ADVANCED RENAL CELL CARCINOMA IN SPAIN
|
Maroto, P
|
|
2006
|
9 |
6 |
p. A280-
1 p.
|
artikel
|
| 123 |
PCN41 COST-EFFECTIVENESS OF TAC VERSUS FAC FOR THE TREATMENT OF NODE POSITIVE BREAST CANCER IN THE ADJUVANT SETTING
|
Fonseca, M
|
|
2006
|
9 |
6 |
p. A288-
1 p.
|
artikel
|
| 124 |
PCN14 COST-EFFECTIVENESS STUDY OF AN ASPIRIN CHEMOPREVENTION ASSOCIATED OR NOT WITH A COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER
|
Francesconi, C
|
|
2006
|
9 |
6 |
p. A280-
1 p.
|
artikel
|
| 125 |
PCN32 COST-MINIMIZATION ANALYSIS OF ORAL VS. IV FLUDARABINE FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) IN BRAZIL
|
Araujo, G
|
|
2006
|
9 |
6 |
p. A285-
1 p.
|
artikel
|
| 126 |
PCN38 “COST OF ILLNESS” ANALYSIS OF RENAL CELL CARCINOMA
|
Lang, K
|
|
2006
|
9 |
6 |
p. A287-
1 p.
|
artikel
|
| 127 |
PCN39 COST-UTILITY ANALYSIS IN A FRENCH SETTING OF ADJUVANT THERAPY WITH HERCEPTIN IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER
|
Fagnani, F
|
|
2006
|
9 |
6 |
p. A287-A288
nvt p.
|
artikel
|
| 128 |
PCN44 COST UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR BREAST CANCER IN THE UK
|
Booth, P
|
|
2006
|
9 |
6 |
p. A289-
1 p.
|
artikel
|
| 129 |
PCN47 COUNTY LEVEL INEQUALITIES IN THE ATTENDANCE OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME
|
Boncz, I
|
|
2006
|
9 |
6 |
p. A290-
1 p.
|
artikel
|
| 130 |
PCN64 DIFFERENTIAL ITEM FUNCTIONING USING RASCH ANALYSIS
|
Brodersen, J
|
|
2006
|
9 |
6 |
p. A295-
1 p.
|
artikel
|
| 131 |
PCN29 ECONOMIC ADVANTAGES AND TIMESAVING OF USING OXALIPLATIN CONCENTRATED SOLUTION VERSUS OXALIPLATIN LYOPHILISED POWDER FOR INFUSION
|
Favier, B
|
|
2006
|
9 |
6 |
p. A284-A285
nvt p.
|
artikel
|
| 132 |
PCN30 ECONOMIC EVALUATION OF FOLFOX4 VERSUS FOLFOX7 WITH OXALIPLATIN STOP-AND-GO IN ADVANCED COLORECTAL CANCER PATIENTS
|
Tilleul, P
|
|
2006
|
9 |
6 |
p. A285-
1 p.
|
artikel
|
| 133 |
PCN34 EFFECT OF METASTASIS LOCALIZATION ON SYMPTOMS AND ASSISTANCE COSTS IN ADVANCED NSCLC PATIENTS. FURTHER EVIDENCE FROM THE HABIT STUDY
|
Negrini, C
|
|
2006
|
9 |
6 |
p. A286-
1 p.
|
artikel
|
| 134 |
PCN3 EPIDEMIOLOGIC, HUMANISTIC AND ECONOMIC BURDEN OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
|
Banks, J
|
|
2006
|
9 |
6 |
p. A276-
1 p.
|
artikel
|
| 135 |
PCN46 EPOIETIN ALPHA TREATMENT FOR CANCER PATIENTS WITH CHEMOTHERAPY INDUCED ANAEMIA–A COSTEFFECTIVENESS ANALYSIS FOR SWEDEN
|
Borg, S
|
|
2006
|
9 |
6 |
p. A289-A290
nvt p.
|
artikel
|
| 136 |
PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY–A COST-SAVING SECOND-LINE TREATMENT OPTION?
|
Gabriel, A
|
|
2006
|
9 |
6 |
p. A278-
1 p.
|
artikel
|
| 137 |
PCN54 ESTIMATING THE CLINICAL BENEFITS OF HPV-16/18 VACCINATION: CHALLENGES OF MODELING PREDICTED CASES OF CERVICAL CANCER IN POLAND AND MEXICO, TWO COUNTRIES WITH DIFFERING DEGREES OF CERVICAL DISEASE AND POPULATION STABILITY
|
Rogoza, RM
|
|
2006
|
9 |
6 |
p. A292-
1 p.
|
artikel
|
| 138 |
PCN49 FACTORS INFLUENCING INEQUITABLE ACCESS TO RADIATION THERAPY: THE CASE STUDY OF CANCER PATIENTS IN THAILAND
|
Prakongsai, P
|
|
2006
|
9 |
6 |
p. A290-A291
nvt p.
|
artikel
|
| 139 |
PCN69 HEALTH UTILITIES IN THE UK FOR SECOND LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PRIOR CHEMOTHERAPY
|
Nafees, B
|
|
2006
|
9 |
6 |
p. A296-A297
nvt p.
|
artikel
|
| 140 |
PCN5 HEXVIX FLUORESCENCE CYSTOSCOPY FOR SUPERFICIAL BLADDER CANCER DIAGNOSIS: ANALYSIS OF BUDGET IMPACT ON THE SWEDISH HEALTH SERVICE
|
Thompson, G
|
|
2006
|
9 |
6 |
p. A277-
1 p.
|
artikel
|
| 141 |
PCN7 IMPACT OF CHANGES IN THE FINANCING OF THE HEALTH SERVICES ON COSTS STRUCTURE ON THE EXAMPLE OF CHEMOTHERAPY OF ADVANCED OVARIAN CANCER
|
Skowron, A
|
|
2006
|
9 |
6 |
p. A277-A278
nvt p.
|
artikel
|
| 142 |
PCN2 INCIDENCE AND SURVIVAL STUDY BY STAGE AND ESTIMATED PREVALENCE OF RENAL PARENCHYMA CANCER IN FRANCE
|
Danzon, A
|
|
2006
|
9 |
6 |
p. A276-
1 p.
|
artikel
|
| 143 |
PCN10 INCREMENTAL COST-EFFECTIVENESS RATIO OF DARBEPOETIN ALFA (ARANESP®) IN THE TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA IN LUNG CANCER PATIENTS
|
Borget, I
|
|
2006
|
9 |
6 |
p. A278-A279
nvt p.
|
artikel
|
| 144 |
PCN55 LONG TERM CLINICAL EFFECT OF AN HPV-VACCINE FOR THE PREVENTION OF CERVICAL CANCER IN FRANCE IN RELATION TO AGE OF VACCINATION: RESULTS FROM A MARKOV MODEL
|
Demarteau, N
|
|
2006
|
9 |
6 |
p. A292-
1 p.
|
artikel
|
| 145 |
PCN56 OUTCOME VALIDATION OF A SUCCINCT HPV INFECTION MODEL FOR FRANCE
|
Demarteau, N
|
|
2006
|
9 |
6 |
p. A293-
1 p.
|
artikel
|
| 146 |
PCN24 PEGFILGRASTIM PRIMARY PROPHYLAXIS IS MORE COSTEFFECTIVE THAN FILGRASTIM IN WOMEN WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN FRANCE
|
Bogillot, O
|
|
2006
|
9 |
6 |
p. A283-
1 p.
|
artikel
|
| 147 |
PCN11 PHARMACOECONOMIC ANALYSES OF ERLOTINIB COMPARED WITH BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTH CARE PERSPECTIVE
|
Côté, I
|
|
2006
|
9 |
6 |
p. A279-
1 p.
|
artikel
|
| 148 |
PCN26 PHARMACOECONOMIC ANALYSIS IN SPAIN OF THERAPY WITH ERLOTINIB, DOCETAXEL, PEMETREXED OR BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE FAILED PREVIOUS CHEMOTHERAPY REGIMENS
|
Rubio Terres, C
|
|
2006
|
9 |
6 |
p. A283-A284
nvt p.
|
artikel
|
| 149 |
PCN51 PHYSICIAN AND PATIENT CHARACTERISTICS ASSOCIATED WITH OUTPATIENT BREAST CANCER SCREENING RECOMMENDATIONS:ANALYSIS OF US OUTPATIENT DATA 1996–2004
|
Balkrishnan, R
|
|
2006
|
9 |
6 |
p. A291-
1 p.
|
artikel
|
| 150 |
PCN58 PRESCRIPTION MEDICATION COSTS TO PROSTATE CANCER PATIENTS: SURVEY RESPONSES COMPARED TO AN ADMINISTRATIVE REGISTER
|
Booth, N
|
|
2006
|
9 |
6 |
p. A293-
1 p.
|
artikel
|
| 151 |
PCN67 PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING WITH 5HT3 RECEPTOR ANTAGONISTS AND HEALTH RELATED QOL
|
García Pulgar, MS
|
|
2006
|
9 |
6 |
p. A296-
1 p.
|
artikel
|
| 152 |
PCN6 PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM IS COSTSAVING COMPARED WITH FILGRASTIM FOR BREAST CANCER IN SPAIN
|
Mayordomo, JI
|
|
2006
|
9 |
6 |
p. A277-
1 p.
|
artikel
|
| 153 |
PCN71 PSYCHOMETRIC EVALUATION OF A PATIENT REPORTED OUTCOME QUESTIONNAIRE FOR METASTATIC COLORECTAL CANCER
|
Mathias, SD
|
|
2006
|
9 |
6 |
p. A297-
1 p.
|
artikel
|
| 154 |
PCN68 QUALITY OF LIFE OF PATIENTS RECEIVING ADJUVANT CHEMOTHERAPIES FOR BREAST CANCER IN JAPAN
|
Fukuda, T
|
|
2006
|
9 |
6 |
p. A296-
1 p.
|
artikel
|
| 155 |
PCN70 RELIABILITY AND VALIDITY OF HEALTH UTILITIES INDEX (HUI) SCORES FOR SURVIVORS OF BRAIN TUMORS IN CHILDHOOD: AGREEMENT BETWEEN PATIENTS AND PARENTS
|
Horsman, JR
|
|
2006
|
9 |
6 |
p. A297-
1 p.
|
artikel
|
| 156 |
PCN21 RETROSPECTIVE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF VARIOUS TREATMENT SCHEMES IN PATIENTS WITH ADVANCED HODGKIN'S DISEASE
|
Tolkushin, AG
|
|
2006
|
9 |
6 |
p. A282-
1 p.
|
artikel
|
| 157 |
PCN8 RISE OF HEALTH RESOURCE UTILIZATION AND COSTS FOR SEQUENTIAL DOCETAXEL IN NODE-POSITIVE PRIMARY BREAST CANCER IN GERMAN HOSPITALS
|
Ihbe-Heffinger, A
|
|
2006
|
9 |
6 |
p. A278-
1 p.
|
artikel
|
| 158 |
PCN52 SCREENING RATE IN THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME
|
Boncz, I
|
|
2006
|
9 |
6 |
p. A291-A292
nvt p.
|
artikel
|
| 159 |
PCN28 SHOULD FOTEMUSTINE BE USED AS THE FIRST LINE TREATMENT
|
Faluta, T
|
|
2006
|
9 |
6 |
p. A284-
1 p.
|
artikel
|
| 160 |
PCN59 THE ECONOMIC VALUE OF INNOVATIVE TREATMENTS OVER THE PRODUCT LIFE CYCLE: THE CASE OF TRASTUZUMAB
|
Garrison, LP
|
|
2006
|
9 |
6 |
p. A293-A294
nvt p.
|
artikel
|
| 161 |
PCN1 THE EPIDEMIOLOGIC, HEALTH-RELATED QUALITY OF LIFE, AND ECONOMIC BURDEN OF GASTROINTESTINAL STROMAL TUMORS
|
Reddy, P
|
|
2006
|
9 |
6 |
p. A275-A276
nvt p.
|
artikel
|
| 162 |
PCN57 TRASTUZUMAB USE FOR METASTATIC BREAST CANCER–IS “MEDIAN TIME TO TREATMENT FAILURE” AN ACCURATE PARAMETER FOR BUDGET IMPACT ANALYSIS?
|
Hammerman, A
|
|
2006
|
9 |
6 |
p. A293-
1 p.
|
artikel
|
| 163 |
PCN25 TREATMENT OF ACTINIC KERATOSIS (AK) AND BASAL CELL CARCINOMA (BCC) WITH METVIX® (MAL-PDT) IN REAL LIFE PRACTICE: A COST OF ILLNESS AND MODEL VALIDATION STUDY
|
Caekelbergh, K
|
|
2006
|
9 |
6 |
p. A283-
1 p.
|
artikel
|
| 164 |
PCN74 UTILITIES ASSOCIATED WITH NON-SMALL CELL LUNG CANCER (NSCLC): A COMMUNITY STUDY
|
Tabberer, M
|
|
2006
|
9 |
6 |
p. A298-
1 p.
|
artikel
|
| 165 |
PCN62 UTILITY ELICITATION IN PATIENTS WITH FOLLICULAR LYMPHOMA
|
Wild, D
|
|
2006
|
9 |
6 |
p. A294-
1 p.
|
artikel
|
| 166 |
PCN73 VARIATIONS IN SATISFACTION WITH CARE AND EMOTIONAL WELL-BEING OF EARLY-STAGE PROSTATE CANCER PATIENTS
|
Jayadevappa, R
|
|
2006
|
9 |
6 |
p. A298-
1 p.
|
artikel
|
| 167 |
PCV60 A CARE MAP FOR CHF IN THE UK
|
Knight, CJ
|
|
2006
|
9 |
6 |
p. A355-A356
nvt p.
|
artikel
|
| 168 |
PCV41 A COST CONSEQUENCE ANALYSIS OF THE IMPACT OF JBS 2 ON PATIENTS ELIGIBLE FOR STATIN TREATMENT IN SCOTLAND
|
Shepherd, J
|
|
2006
|
9 |
6 |
p. A349-A350
nvt p.
|
artikel
|
| 169 |
PCV40 A COST-EFFECTIVENESS ANALYSIS OF CARDIAC REHABILITATION AFTER PERCUTANEOUS CORONARY INTERVENTIONS
|
Lamotte, M
|
|
2006
|
9 |
6 |
p. A349-
1 p.
|
artikel
|
| 170 |
PCV34 A COST-EFFECTIVENESS ANALYSIS OF OLMESARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION
|
Lamotte, M
|
|
2006
|
9 |
6 |
p. A347-
1 p.
|
artikel
|
| 171 |
PCV36 A HEALTH ECONOMIC EVALUATION OF CONCOMITANT SURGICAL ABLATION FOR ATRIAL FIBRILLATION
|
Lamotte, M
|
|
2006
|
9 |
6 |
p. A348-
1 p.
|
artikel
|
| 172 |
PCV73 ANALYSIS OF COST AND EFFECTIVENESS DATA USING RANDOM PERMUTATION METHODS
|
Kolm, P
|
|
2006
|
9 |
6 |
p. A359-A360
nvt p.
|
artikel
|
| 173 |
PCV15 ANALYSIS OF PRESCRIBING PATTERNS OF ANTIHYPERTENSIVE AGENTS (AA) BEFORE AND AFTER PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPIDLOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)
|
Brixner, D
|
|
2006
|
9 |
6 |
p. A341-
1 p.
|
artikel
|
| 174 |
PCV72 ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) FOR MILD TO MODERATE HYPERTENSION:A LITERATURE REVIEW
|
Maniadakis, N
|
|
2006
|
9 |
6 |
p. A359-
1 p.
|
artikel
|
| 175 |
PCV21 ANTIHYPERTENSIVE DRUG BUDGET IMPACT OF THE ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN THE UK
|
Blak, BT
|
|
2006
|
9 |
6 |
p. A343-
1 p.
|
artikel
|
| 176 |
PCV14 ASCOT-LIKE PATIENT PREVALENCE AMONG THE HYPERTENSIVES IN SPAIN
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A341-
1 p.
|
artikel
|
| 177 |
PCV24 CARDIOVASCULAR EVENTS REDUCTION AND COSTEFFECTIVENESS OF ATORVASTATIN VERSUS PRAVASTATIN IN SPANISH POPULATION WITH ACUTE CORONARY SYNDROME (ACS)
|
F Bobadilla, J
|
|
2006
|
9 |
6 |
p. A344-
1 p.
|
artikel
|
| 178 |
PCV2 CARDIOVASCULAR RISK FACTORS IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN FIVE EUROPEAN COUNTRIES
|
McCollam, PL
|
|
2006
|
9 |
6 |
p. A337-
1 p.
|
artikel
|
| 179 |
PCV86 CHARACTERIZATION OF HYPERTENSIVE PATIENTS WHO MIGHT BENEFIT FROM A COMBINATION OF TWO DRUGS IN ONE PILL FOR REDUCTION OF CARDIOVASCULAR RISK
|
Sturkenboom, MC
|
|
2006
|
9 |
6 |
p. A363-A364
nvt p.
|
artikel
|
| 180 |
PCV79 CLASSIFYING PATIENTS WITH DYSLIPIDEMIA: A LATENT CLASS ANALYSIS
|
Liu, GG
|
|
2006
|
9 |
6 |
p. A361-A362
nvt p.
|
artikel
|
| 181 |
PCV11 CLINICAL EFFECTIVENESS OF BETALOC ZOC COMPARED TO METOPROLOL TARTRATE OR CARVEDILOL IN HYPERTENSION TREATMENT
|
Kawalec, P
|
|
2006
|
9 |
6 |
p. A340-
1 p.
|
artikel
|
| 182 |
PCV1 CLINICAL IMPACT OF DIAGNOSTIC IMAGING OF LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE
|
Scranton, R
|
|
2006
|
9 |
6 |
p. A337-
1 p.
|
artikel
|
| 183 |
PCV68 CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN 5 EUROPEAN COUNTRIES
|
Smith, H
|
|
2006
|
9 |
6 |
p. A358-
1 p.
|
artikel
|
| 184 |
PCV44 COMORBIDITIES, COSTS AND THERAPEUTIC GOALS ACHIEVED IN THE SECONDARY PREVENTION OF THE PRIMARY HEALTH CARE
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A350-A351
nvt p.
|
artikel
|
| 185 |
PCV87 COMPARING COMPLIANCE AND PERSISTENCE RATES FOR HYPERTENSION, DYSLIPIDEMIA, AND DIABETES MEDICATIONS
|
Cramer, JA
|
|
2006
|
9 |
6 |
p. A364-
1 p.
|
artikel
|
| 186 |
PCV85 COMPLIANCE AND PERSISTENCE OF FIXED DOSE VERSUS FREE DOSE COMBINATION THERAPY WITH VALSARTAN AND HCTZ FOR PATIENTS WITH HYPERTENSION
|
Jackson, KC
|
|
2006
|
9 |
6 |
p. A363-
1 p.
|
artikel
|
| 187 |
PCV84 COMPLIANCE IMPROVEMENTS AND HDL CHOLESTEROL LEVELS IN HYPERTENSIVE PATIENTS IN SPAIN
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A363-
1 p.
|
artikel
|
| 188 |
PCV83 COMPLIANCE PATTERN OF PHARMACOLOGICAL REGIMENS IN HYPERTENSIVES AND/OR DYSLIPIDEMIC PATIENTS IN AMBULATORY CARE IN A SPANISH POPULATION
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A362-A363
nvt p.
|
artikel
|
| 189 |
PCV43 COST ANALYSIS OF TREATMENT WITH NESIRITIDE FOR ACUTE DECOMPENSATED HEART FAILURE IN A BRAZILIAN SETTING
|
Pereira, M
|
|
2006
|
9 |
6 |
p. A350-
1 p.
|
artikel
|
| 190 |
PCV74 COST-EFFECTIVENESS ANALYSIS IN CORONARY ARTERY DISEASE DIAGNOSIS: CHOOSING BETWEEN LABORATORY MARKERS
|
Bogavac-Stanojevic, N
|
|
2006
|
9 |
6 |
p. A360-
1 p.
|
artikel
|
| 191 |
PCV54 COST-EFFECTIVENESS ANALYSIS OF DIAGNOSTIC METHODS IN THE MANAGEMENT OF PATIENTS WITH SYMPTOMATIC, LOWER LIMB PERIPHERAL ARTERIAL DISEASE
|
Aguiar-Ibáñez, R
|
|
2006
|
9 |
6 |
p. A353-A354
nvt p.
|
artikel
|
| 192 |
PCV29 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN TREATING PATIENTS TO LDL-C ATP III GOALS. A MEXICAN PERSPECTIVE OF THE STELLAR TRIAL
|
Soto, H
|
|
2006
|
9 |
6 |
p. A346-
1 p.
|
artikel
|
| 193 |
PCV33 COST-EFFECTIVENESS MODEL TO EVALUATE MANAGED VENTRICULAR PACING (MVP) IMPLANTED IN A SPANISH AMBULATORY SURGERY PROGRAM
|
Rodríguez, J
|
|
2006
|
9 |
6 |
p. A347-
1 p.
|
artikel
|
| 194 |
PCV10 COST-EFFECTIVENESS OF A LIFESTYLE INTERVENTION FOR HYPERTENSION: AN OPEN RANDOMISED CONTROLLED TRIAL
|
Martikainen, JA
|
|
2006
|
9 |
6 |
p. A340-
1 p.
|
artikel
|
| 195 |
PCV27 COST-EFFECTIVENESS OF BETALOC COMPARED TO CARVEDILOL IN CARDIAC INSUFFICIENCY AND ARTERIAL HYPERTENSION TREATMENT IN POLAND
|
Kawalec, P
|
|
2006
|
9 |
6 |
p. A345-
1 p.
|
artikel
|
| 196 |
PCV26 COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO: A LONG TERM ANALYSIS
|
Jerjes-Sanchez, C
|
|
2006
|
9 |
6 |
p. A345-
1 p.
|
artikel
|
| 197 |
PCV25 COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO: WITHIN TRIAL ANALYSIS
|
Jerjes-Sanchez, C
|
|
2006
|
9 |
6 |
p. A344-
1 p.
|
artikel
|
| 198 |
PCV32 COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION: EUROPEAN MODEL RESULTS BASED ON CLARITY AND COMMIT
|
Berg, J
|
|
2006
|
9 |
6 |
p. A346-A347
nvt p.
|
artikel
|
| 199 |
PCV28 COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT IN SECONDARY CARDIOVASCULAR PREVENTION IN SPAIN AND GERMANY
|
Taylor, DC
|
|
2006
|
9 |
6 |
p. A345-
1 p.
|
artikel
|
| 200 |
PCV37 COST-EFFECTIVENESS OF LONG-TERM TREATMENT OF HYPERTENSION WITH IRBESARTAN VS. LOSARTAN OR NO TREATMENT IN DENMARK
|
Knudsen, MS
|
|
2006
|
9 |
6 |
p. A348-
1 p.
|
artikel
|
| 201 |
PCV30 COST-EFFECTIVENESS OF ROSUVASTATIN FOR CARDIOVASCULAR PREVENTION IN HIGH-RISK POPULATIONS IN SWEDEN
|
Jönsson, L
|
|
2006
|
9 |
6 |
p. A346-
1 p.
|
artikel
|
| 202 |
PCV22 COST IMPACT OF DIAGNOSTIC IMAGING FOR LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE (PVD)
|
Hay, JW
|
|
2006
|
9 |
6 |
p. A343-
1 p.
|
artikel
|
| 203 |
PCV38 COST MINIMIZATION ANALYSIS OF BIVALIRUDIN VERSUS HEPARIN PLUS PLANNED ABXICIMAB IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
|
Cequier, Á
|
|
2006
|
9 |
6 |
p. A348-A349
nvt p.
|
artikel
|
| 204 |
PCV45 COST OF CHRONIC VENOUS INSUFFICIENCY (CVI) IN POLAND
|
Bartminski, W
|
|
2006
|
9 |
6 |
p. A351-
1 p.
|
artikel
|
| 205 |
PCV57 COSTS ASSOCIATED WITH DRUG USE IN THE NONADHERENCE TO CHOLESTEROL MANAGEMENT GUIDELINES FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN AN ELDERLY POPULATION:THE ROTTERDAM STUDY
|
Gumbs, PD
|
|
2006
|
9 |
6 |
p. A354-A355
nvt p.
|
artikel
|
| 206 |
PCV53 COST-UTILITY ANALYSIS OF EPROSARTAN COMPARED TO ENALAPRIL AND RAMIPRIL IN THE TREATMENT OF MODERATE TO SEVERE HYPERTENSION IN SWEDEN
|
Lindgren, P
|
|
2006
|
9 |
6 |
p. A353-
1 p.
|
artikel
|
| 207 |
PCV49 COST-UTILITY ANALYSIS USING A MARKOV MODEL TO COMPARE PRESCRIPTION STATINS VERSUS POTENTIAL OVER THE COUNTER STATINS IN USA
|
Gandhi, PK
|
|
2006
|
9 |
6 |
p. A352-
1 p.
|
artikel
|
| 208 |
PCV75 DERIVING COST INPUT VALUES FOR USE IN A MARKOV MODEL FOR EXPLORING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN OVERWEIGHT OR OBESE SUBJECTS
|
McEwan, P
|
|
2006
|
9 |
6 |
p. A360-
1 p.
|
artikel
|
| 209 |
PCV80 DERIVING UTITLITY VALUES FOR USE IN A MARKOV MODEL FOR EXPLORING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN OVERWEIGHT OR OBESE SUBJECTS
|
McEwan, P
|
|
2006
|
9 |
6 |
p. A362-
1 p.
|
artikel
|
| 210 |
PCV63 DEVELOPING HOSPICE DRUG FORMULARIES USING MULTIATTRIBUTE UTILITY THEORY (MAUT) METHOD AND THE EVALUATION OF THEIR ECONOMIC IMPACT
|
Khandelwal, NG
|
|
2006
|
9 |
6 |
p. A356-A357
nvt p.
|
artikel
|
| 211 |
PCV90 DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ATRIAL FIBRILLATION:“AF-QOL”
|
Arribas, F
|
|
2006
|
9 |
6 |
p. A365-
1 p.
|
artikel
|
| 212 |
PCV47 DIRECT MEDICAL COSTS FOR TREATMENT OF MILD TO MODERATE HYPERTENSION IN PATIENTS WITH TYPE II DIABETES
|
Berto, P
|
|
2006
|
9 |
6 |
p. A351-
1 p.
|
artikel
|
| 213 |
PCV19 DISCONTINUED USE OF MYCOPHENOLATE MOFETIL AND GRAFT LOSS IN HEART TRANSPLANT RECIPIENTS
|
Legorreta, AP
|
|
2006
|
9 |
6 |
p. A342-
1 p.
|
artikel
|
| 214 |
PCV77 DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS
|
Jahn, B
|
|
2006
|
9 |
6 |
p. A361-
1 p.
|
artikel
|
| 215 |
PCV3 DO WE FOLLOW THE GUIDELINES ON PREVENTION OF CARDIOVASCULAR DISEASE IN OUT-PATIENT CARE?
|
Pietrasik, A
|
|
2006
|
9 |
6 |
p. A337-A338
nvt p.
|
artikel
|
| 216 |
PCV5 DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN LONG-TERM CLINICAL OUTCOMES
|
Eisenstein, EL
|
|
2006
|
9 |
6 |
p. A338-
1 p.
|
artikel
|
| 217 |
PCV62 DRUG USE EVALUATION OF ROSUVASTATIN IN A HONG KONG PUBLIC HOSPITAL
|
Lee, VWY
|
|
2006
|
9 |
6 |
p. A356-
1 p.
|
artikel
|
| 218 |
PCV65 ECONOMIC APPRAISAL OF THE ANGIOPLASTY PROCEDURES PERFORMED IN 2004 IN A HIGH-VOLUME DIAGNOSTIC AND SURGICAL CARDIOLOGY UNIT
|
Ponzi, P
|
|
2006
|
9 |
6 |
p. A357-
1 p.
|
artikel
|
| 219 |
PCV23 ECONOMIC BURDEN OF CONTRAST-INDUCEDNEPHROPATHY (CIN): IMPLICATIONS FOR PREVENTION STRATEGIES
|
Subramanian, S
|
|
2006
|
9 |
6 |
p. A344-
1 p.
|
artikel
|
| 220 |
PCV51 ECONOMIC EVALUATION OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) IN THE UK
|
Ratcliffe, A
|
|
2006
|
9 |
6 |
p. A353-
1 p.
|
artikel
|
| 221 |
PCV55 ECONOMIC EVALUATION OF DRUG ELUTING STENTS: COST-UTILITY ANALYSIS
|
Bischof, M
|
|
2006
|
9 |
6 |
p. A354-
1 p.
|
artikel
|
| 222 |
PCV13 EFFECT OF ABSOLUTE REDUCTION IN LDL CHOLESTEROL ON CARDIOVASCULAR EVENTS: DOES FINAL LDL CHOLESTEROL ACHEIVED MATTER?
|
Rahilly, CR
|
|
2006
|
9 |
6 |
p. A340-A341
nvt p.
|
artikel
|
| 223 |
PCV50 EFFICACY AND SOCIOECONOMIC RELEVANCE OF HAWTHORN EXTRACT (CRATAEGUS) WS® 1442 IN THE TREATMENT OF NYHA II CHF PATIENTS—RESULTS FROM A PROSPECTIVE THREE-YEAR PHARMACOECONOMIC STUDY
|
Rychlik, R
|
|
2006
|
9 |
6 |
p. A352-
1 p.
|
artikel
|
| 224 |
PCV35 ESTIMATING LIFETIME COSTS AND LIFE EXPECTANCY ASSOCIATED WITH CARDIOVASCULAR DISEASE IN A SWISS POPULATION WITH AND WITHOUT METABOLIC SYNDROME
|
Ray, J
|
|
2006
|
9 |
6 |
p. A347-A348
nvt p.
|
artikel
|
| 225 |
PCV56 ESTIMATION OF THE PRESENCE OF CARDIOVASCULAR EVENTS AND DIRECT COSTS ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AN AMBULATORY SETTING
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A354-
1 p.
|
artikel
|
| 226 |
PCV20 FINANCIAL IMPACT OF EPLERENONE USE IN A SPANISH REFERENCE HOSPITAL
|
F Bobadilla, J
|
|
2006
|
9 |
6 |
p. A343-
1 p.
|
artikel
|
| 227 |
PCV31 HEALTH ECONOMIC ASSESSMENT OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) WHEN ADDED TO STATIN THERAPY IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES:AN ANALYSIS FOR SWEDEN
|
Renaudin, C
|
|
2006
|
9 |
6 |
p. A346-
1 p.
|
artikel
|
| 228 |
PCV42 IMPACT OF VENTRICULAR ARRHYTHMIAS ON HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (AMI)
|
Iyer, S
|
|
2006
|
9 |
6 |
p. A350-
1 p.
|
artikel
|
| 229 |
PCV61 INITIAL PHARMACOTHERAPY FOR PATIENTS WITH DYSLIPIDEMIA IN PRIMARY CARE
|
Luo, N
|
|
2006
|
9 |
6 |
p. A356-
1 p.
|
artikel
|
| 230 |
PCV59 LIPID TESTING AMONG PATIENTS RECEIVING FIRST-EVER STATIN THERAPY IN UK GENERAL PRACTICES
|
Phatak, H
|
|
2006
|
9 |
6 |
p. A355-
1 p.
|
artikel
|
| 231 |
PCV52 LOSARTAN-BASED VERSUS ATENOLOL-BASED THERAPY IN PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY: AN ECONOMIC EVALUATION OF THE LOSARTAN INTERVENTION FOR ENDPOINT REDUCTION IN HYPERTENSION (LIFE) STUDY FOR GERMANY
|
Krobot, KJ
|
|
2006
|
9 |
6 |
p. A353-
1 p.
|
artikel
|
| 232 |
PCV16 MAIN CARDIOVASCULAR RISK FACTORS: ASSOCIATION AND CONTROL IN A PRIMARY HEALTH CARE SETTING
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A341-A342
nvt p.
|
artikel
|
| 233 |
PCV70 MANAGEMENT AND OUTCOMES IN THE CARE OF ATRIAL FIBRILLATION IN GERMANY (MOCA)
|
Bruggenjurgen, B
|
|
2006
|
9 |
6 |
p. A358-A359
nvt p.
|
artikel
|
| 234 |
PCV88 MEDICATION TREATMENT PATTERNS FOR DYSLIPIDEMIA IN US
|
Zhao, Z
|
|
2006
|
9 |
6 |
p. A364-
1 p.
|
artikel
|
| 235 |
PCV48 MEDICATION USE AND ASSOCIATED ANNUAL COSTS IN PATIENTS AT RISK OF ATHEROTHROMBOSIS: RESULTS FOR GERMANY, SPAIN AND THE UK FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY
|
Mahoney, EM
|
|
2006
|
9 |
6 |
p. A352-
1 p.
|
artikel
|
| 236 |
PCV4 META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF PRESSURE MEASUREMENTS IN CORONARY ARTERY DISEASE
|
Bornschein, B
|
|
2006
|
9 |
6 |
p. A338-
1 p.
|
artikel
|
| 237 |
PCV46 NON-HOSPITAL COSTS AND NUMBER OF CARDIOVASCULAR RISK FACTORS (CVRF) IN SPANISH HIPERTENSIVE PATIENTS
|
F Bobadilla, J
|
|
2006
|
9 |
6 |
p. A351-
1 p.
|
artikel
|
| 238 |
PCV9 NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO INCREASED RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION OR STROKE
|
Breekveldt-Postma, NS
|
|
2006
|
9 |
6 |
p. A339-
1 p.
|
artikel
|
| 239 |
PCV18 OUTCOME OF THIAZOLIDINEDIONE USE IN DISCHARGED DIABETIC PATIENTS WHO WERE HOSPITALIZED FOR HEART FAILURE
|
Chou, HY
|
|
2006
|
9 |
6 |
p. A342-
1 p.
|
artikel
|
| 240 |
PCV71 PHARMACOECONOMIC ANALYSIS OF TREATMENT OF HYPERTENSION IN CLINICAL CENTER OF SERBIAPHARMACY AND MEDICAL SUPPLY
|
Simic, G
|
|
2006
|
9 |
6 |
p. A359-
1 p.
|
artikel
|
| 241 |
PCV39 PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE II DIABETES A COST-MINIMIZATION ANALYSIS
|
Berto, P
|
|
2006
|
9 |
6 |
p. A349-
1 p.
|
artikel
|
| 242 |
PCV67 PROJECTED COST SAVINGS TO THIRD PARTY PAYERS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AVAILABILITY IN USA
|
Gandhi, PK
|
|
2006
|
9 |
6 |
p. A357-A358
nvt p.
|
artikel
|
| 243 |
PCV17 PROJECTED IMPACT ON CORONARY HEART DISEASE OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN EUROPEAN PATIENTS WITH TYPE 2 DIABETES
|
Liens, D
|
|
2006
|
9 |
6 |
p. A342-
1 p.
|
artikel
|
| 244 |
PCV91 PSICOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) IN HIPERTENSIVE PATIENTS
|
Ruíz, MA
|
|
2006
|
9 |
6 |
p. A365-
1 p.
|
artikel
|
| 245 |
PCV7 REACHING AWMSG TARGETS AND BEYOND-A RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN WELSH GENERAL PRACTICE
|
Moore, RP
|
|
2006
|
9 |
6 |
p. A339-
1 p.
|
artikel
|
| 246 |
PCV6 REACHING SIGN CHOLESTEROL TARGETS AND BEYOND: RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN A SCOTTISH GENERAL PRACTICE
|
Burnett, GR
|
|
2006
|
9 |
6 |
p. A338-A339
nvt p.
|
artikel
|
| 247 |
PCV69 RETROSPECTIVE STUDY OF CLOPIDOGREL USE AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) UNDERGOING CORONARY ARTERY BYPASS GRAFT
|
Hauch, O
|
|
2006
|
9 |
6 |
p. A358-
1 p.
|
artikel
|
| 248 |
PCV8 THE EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH OTHER STATINS—RESULTS FROM A ROUTINE CLINICAL PRACTICE SETTING IN THE UK
|
Hirsch, MW
|
|
2006
|
9 |
6 |
p. A339-
1 p.
|
artikel
|
| 249 |
PCV76 THE GERMAN CARDIOMETABOLIC COST DATABASE—A METHODOLOGICAL APPROACH TO ASSESS COST DATA FOR MODELLING COST-EFFECTIVENESS OF TREATMENT REGIMES FOR PATIENTS WITH MULTIPLE CARDIOMETABOLIC RISK FACTORS
|
Fuchs, SM
|
|
2006
|
9 |
6 |
p. A360-
1 p.
|
artikel
|
| 250 |
PCV89 THE RELATIONSHIP BETWEEN PATIENT BELIEFS AND ADHERENCE TO CHOLESTEROL-LOWERING MEDICATIONS: IMPLICATIONS FOR DISEASE MANAGEMENT PROGRAMS
|
Hansen, LG
|
|
2006
|
9 |
6 |
p. A364-A365
nvt p.
|
artikel
|
| 251 |
PCV58 THE ROLE OF ECONOMIC FACTORS IN THERAPEUTIC DECISION MAKING CONCERNING TREATMENT OF CORONARY ARTERY DISEASE IN POLAND
|
Banasiak, W
|
|
2006
|
9 |
6 |
p. A355-
1 p.
|
artikel
|
| 252 |
PCV66 THE VALUE OF MYOCARDIAL PERFUSION SCINTIGRAPHY (MPS) IN CORONARY ARTERY DISEASE (CAD):A REVIEW OF THE ECONOMIC LITERATURE SUBMITTED TO THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)
|
Sidhu, MK
|
|
2006
|
9 |
6 |
p. A357-
1 p.
|
artikel
|
| 253 |
PCV78 TOWARDS A MODELLED ECONOMIC EVALUATION TO IDENTIFY THE OPTIMAL POPULATION FOR SCREENING OF CORONARY ARTERY DISEASE
|
Tilden, D
|
|
2006
|
9 |
6 |
p. A361-
1 p.
|
artikel
|
| 254 |
PCV82 VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATINTREATED PATIENTS WITH PERSISTENTLY LOW HDL-C
|
Renaudin, C
|
|
2006
|
9 |
6 |
p. A362-
1 p.
|
artikel
|
| 255 |
PCV81 VALIDATION OF THE MODE OF ADMINISTRATION OF THE MEDICATION COMPLIANCE QUESTIONNAIRE
|
Rosa, K
|
|
2006
|
9 |
6 |
p. A362-
1 p.
|
artikel
|
| 256 |
PDB27 A COST-UTILITY ANALYSIS OF ORLISTAT (XENICAL®) IN THE TREATMENT OF DIABETIC PATIENTS WITH MORBID OBESITY AND ADDITIONAL CVD RISK IN NORWAY
|
Sverre, JM
|
|
2006
|
9 |
6 |
p. A232-
1 p.
|
artikel
|
| 257 |
PDB38 ADHERENCE TO STATIN TREATMENT IN PEOPLE WITH TYPE 1 AND TYPE 2 DIABETES
|
Donnan, PT
|
|
2006
|
9 |
6 |
p. A236-
1 p.
|
artikel
|
| 258 |
PDB32 AMPUTATIONS IN DIABETIC FOOT ULCER PATIENTS USING NPWT
|
Keith, MS
|
|
2006
|
9 |
6 |
p. A234-
1 p.
|
artikel
|
| 259 |
PDB2 AN EVALUATION OF DIABETES CONTROL AND REPORTS OF HYPOGLYCAEMIA IN UK GENERAL PRACTICE FOLLOWING INITIATION OF INSULIN GLARGINE VERSUS INSULIN DETEMIR USING OBSERVATIONAL, REAL-LIFE DATA
|
Currie, CJ
|
|
2006
|
9 |
6 |
p. A224-
1 p.
|
artikel
|
| 260 |
PDB4 AN EVALUATION OF THE COST OF DIABETES-RELATED MEDICATION FOLLOWING INITIATION OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN THE UK FROM OBSERVATIONAL, REAL-LIFE DATA FROM GENERAL PRACTICE
|
Poole, CD
|
|
2006
|
9 |
6 |
p. A224-A225
nvt p.
|
artikel
|
| 261 |
PDB34 A POPULATION-BASED STUDY OF THE TIME TO INSULIN INITIATION/INTENSIFICATION AFTER FAILURE ON CURRENT THERAPY IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN THE UK
|
Calvert, MJ
|
|
2006
|
9 |
6 |
p. A234-A235
nvt p.
|
artikel
|
| 262 |
PDB47 A USEFUL TOOL FOR EVALUATING THE FEAR OF INJECTING AND SELF-TESTING IN DIABETIC PATIENTS:THE SPANISH VERSION OF THE DIABETES FEAR OF INJECTING AND SELF-TESTING QUESTIONNAIRE (D-FISQ)
|
Rebollo, P
|
|
2006
|
9 |
6 |
p. A238-A239
nvt p.
|
artikel
|
| 263 |
PDB1 BETTER HBA1C CONTROL WITH BOT VERSUS CT AVOIDS LONG-TERM MICRO-VASCULAR COMPLICATIONS IN PATIENTS WITH TYPE-2-DIABETES: MODEL SIMULATIONS WITH THE DMM
|
Walzer, S
|
|
2006
|
9 |
6 |
p. A223-A224
nvt p.
|
artikel
|
| 264 |
PDB19 COMPARATIVE OUTCOMES-BASED HEALTH ECONOMIC EVALUATION OF TYPE 2 DIABETES PATIENTS ON BASAL INSULIN ANALOGS
|
Cobden, D
|
|
2006
|
9 |
6 |
p. A229-A230
nvt p.
|
artikel
|
| 265 |
PDB29 COMPARING THE DEVELOPMENT OF A GERMAN DIABETES POPULATION WITH RESPECT TO LONGTERM OUTCOMES USING DATA FROM THE DETECT STUDY AND THE EAGLE DIABETES SIMULATION MODEL
|
Mueller, E
|
|
2006
|
9 |
6 |
p. A233-
1 p.
|
artikel
|
| 266 |
PDB12 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTION OF INSULIN IN PATIENTS WITH TYPE 1 DIABETES:A LONG-TERM HEALTH ECONOMIC ANALYSIS IN THE NORWEGIAN AND SWEDISH SETTINGS
|
Goodall, G
|
|
2006
|
9 |
6 |
p. A227-
1 p.
|
artikel
|
| 267 |
PDB18 COST-EFFECTIVENESS OF ACARBOSE IN PATIENTS WITH TYPE-2 DIABETES IN THREE COUNTRIES
|
Evers, T
|
|
2006
|
9 |
6 |
p. A229-
1 p.
|
artikel
|
| 268 |
PDB35 COST-EFFECTIVENESS OF INHALED INSULIN IN PATIENTS WITH DIABETES UNCONTROLLED ON THEIR CURRENT THERAPY: THE UK BASE CASE SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)
|
Plun-Favreau, J
|
|
2006
|
9 |
6 |
p. A235-
1 p.
|
artikel
|
| 269 |
PDB26 COST-EFFECTIVENESS OF ROSIGLITAZONE FOR TREATMENT OF TYPE 2 DIABETES IN PORTUGAL USING DIFFERENT METHODS TO MODEL CLINICAL EFFECTS
|
TaylorJ, MJ
|
|
2006
|
9 |
6 |
p. A232-
1 p.
|
artikel
|
| 270 |
PDB6 COST-EFFECTIVENESS OF THE ONE-TOUCH® ULTRASMART® BLOOD GLUCOSE METER COMPARED WITH A CONVENTIONAL METER FOR INSULIN-USING DIABETES PATIENTS FROM THE USA
|
Minshall, ME
|
|
2006
|
9 |
6 |
p. A225-
1 p.
|
artikel
|
| 271 |
PDB24 COST OF A MAJOR HYPOGLYCAEMIC EVENT IN TYPE 1 AND TYPE 2 DIABETIC PATIENTS-A SYSTEMATIC LITERATURE REVIEW
|
Lilja, U
|
|
2006
|
9 |
6 |
p. A231-
1 p.
|
artikel
|
| 272 |
PDB25 COST OF INPATIENT AND OUTPATIENT CARE OF SWEDISH PATIENTS WITH DIABETES MELLITUS
|
Ringborg, A
|
|
2006
|
9 |
6 |
p. A231-A232
nvt p.
|
artikel
|
| 273 |
PDB14 DIRECT COST FOR CONTROL OF DM IN A RURAL AREAS
|
Avila-LaChica, L
|
|
2006
|
9 |
6 |
p. A228-
1 p.
|
artikel
|
| 274 |
PDB30 DRUGS USE IN DIABETIC PATIENTS
|
Cammarota, S
|
|
2006
|
9 |
6 |
p. A233-
1 p.
|
artikel
|
| 275 |
PDB21 ECONOMIC EVALUATION OF INITIATING INSULIN DETEMIR AMONG TYPE 2 DIABETES PATIENTS RECEIVING ORAL MEDICATION
|
Palmer, AJ
|
|
2006
|
9 |
6 |
p. A230-
1 p.
|
artikel
|
| 276 |
PDB41 EFFECT OF COMPLICATIONS ON HEALTH RELATED QUALITY OF LIFE IN HUNGARIAN INSULIN TREATED DIABETIC PATINETS
|
Brodszky, V
|
|
2006
|
9 |
6 |
p. A237-
1 p.
|
artikel
|
| 277 |
PDB43 EFFECT OF INSULIN GLARGINE AND NPH ON QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
Gupta, K
|
|
2006
|
9 |
6 |
p. A237-
1 p.
|
artikel
|
| 278 |
PDB22 EVALUATING THE LONG-TERM HEALTH OUTCOMES AND ECONOMICS OF INITIATING BIPHASIC ANALOG INSULIN COMPARED TO OPTIMIZED ORAL THERAPY ALONE
|
Valentine, WJ
|
|
2006
|
9 |
6 |
p. A230-A231
nvt p.
|
artikel
|
| 279 |
PDB45 EXPERIENCE OF HYPOGLYCEMIA IS SIGNIFICANTLY ASSOCIATED WITH LOWER QUALITY OF LIFE (EUROQOL) IN DIABETIC PATIENTS TREATED WITH METFORMIN (MF) IN COMBINATION WITH A SULPHONYLUREA (SU) IN FRANCE
|
Mavros, P
|
|
2006
|
9 |
6 |
p. A238-
1 p.
|
artikel
|
| 280 |
PDB44 EXPLORING DIFFERENCES IN PATIENT VERSUS PUBLIC PREFERENCES IN HEALTH UTILITIES:A QUALITATIVE STUDY
|
Lloyd, A
|
|
2006
|
9 |
6 |
p. A237-A238
nvt p.
|
artikel
|
| 281 |
PDB40 HEALTH-RELATED QUALITY OF LIFE OF TYPE 2 DIABETICS IN GERMAN PRIMARY CARE: RESULTS OF THE DETECT STUDY
|
Pieper, L
|
|
2006
|
9 |
6 |
p. A236-
1 p.
|
artikel
|
| 282 |
PDB28 INADEQUATE GLYCEMIC CONTROL: IS IT RELATED WITH MORE COMORBIDITIES AND MORE RESOURCE UTILIZATION?
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A232-A233
nvt p.
|
artikel
|
| 283 |
PDB10 LONG-TERM CLINICAL AND ECONOMIC OUTCOMES FOR PATIENTS WITH TYPE 1 DIABETES TREATED WITH INSULIN ASPART VERSUS HUMAN SOLUBLE INSULIN IN SWEDEN
|
Tucker, D
|
|
2006
|
9 |
6 |
p. A226-A227
nvt p.
|
artikel
|
| 284 |
PDB11 LONG-TERM COST-EFFECTIVENESS ANALYSIS OF REPAGLINIDE VERSUS NATEGLINIDE IN COMBINATION WITH METFORMIN IN TYPE 2 DIABETES PATIENTS FAILING MONOTHERAPY IN THE SWEDISH SETTING
|
Ray, J
|
|
2006
|
9 |
6 |
p. A227-
1 p.
|
artikel
|
| 285 |
PDB48 MANAGEMENT AND TREATMENT ADHERENCE IN TYPE 2 DIABETIC PATIENTS IN SPAIN
|
Secnik, K
|
|
2006
|
9 |
6 |
p. A239-
1 p.
|
artikel
|
| 286 |
PDB50 MYTHS AND REALITIES OF TREATMENT SATISFACTION IN DIABETES
|
Brod, M
|
|
2006
|
9 |
6 |
p. A239-A240
nvt p.
|
artikel
|
| 287 |
PDB42 PATIENT AND PHYSICIAN DRIVERS OF HEALTH-RELATED QUALITY LIFE OF PATIENTS WITH TYPE 2 DIABETES IN PRIMARY CARE IN SPAIN
|
Yurgin, NR
|
|
2006
|
9 |
6 |
p. A237-
1 p.
|
artikel
|
| 288 |
PDB5 PREVENTION WITH PICOTAMIDE AND ASPIRIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND PERIPHERAL ARTERIAL DISEASE:A PHARMACOECONOMIC EVALUATION
|
Iannazzo, S
|
|
2006
|
9 |
6 |
p. A225-
1 p.
|
artikel
|
| 289 |
PDB46 QUANTIFYING THE IMPACT OF FEAR OF HYPOGLYCAEMIA ON QUALITY OF LIFE
|
Walters, N
|
|
2006
|
9 |
6 |
p. A238-
1 p.
|
artikel
|
| 290 |
PDB31 REIMBURSEMENT OF PHARMACEUTICALS AND BRANDGENERIC DRUG UTILIZATION: EVIDENCE FROM ORAL HYPOGLYCEMIC AGENTS FOR AMBULATORY CARE IN TAIWAN
|
Liu, YM
|
|
2006
|
9 |
6 |
p. A233-A234
nvt p.
|
artikel
|
| 291 |
PDB37 SCORING AND PSYCHOMETRIC VALIDATION OF A SCALE FOR DIABETIC PATIENT PROFILING BASED ON PATIENT ATTITUDE TOWARDS INSULIN
|
Arnould, B
|
|
2006
|
9 |
6 |
p. A235-A236
nvt p.
|
artikel
|
| 292 |
PDB16 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES: COST UTILITY ANALYSIS IN A FRENCH GOVENMENT PAYER SETTING
|
Palmer, AJ
|
|
2006
|
9 |
6 |
p. A228-A229
nvt p.
|
artikel
|
| 293 |
PDB17 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES: COST UTILITY ANALYSIS IN A GERMAN GOVENMENT PAYER SETTING
|
Palmer, AJ
|
|
2006
|
9 |
6 |
p. A229-
1 p.
|
artikel
|
| 294 |
PDB15 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES: COST UTILITY ANALYSIS IN AN ITALIAN SETTING
|
Palmer, AJ
|
|
2006
|
9 |
6 |
p. A228-
1 p.
|
artikel
|
| 295 |
PDB3 THE COST-BENEFIT OF KERRABOOT USE IN DIABETIC FOOT ULCER MANAGEMENT
|
Knight, AD
|
|
2006
|
9 |
6 |
p. A224-
1 p.
|
artikel
|
| 296 |
PDB23 THE COST-EFFECTIVENESS OF INHALED INSULIN IN SWEDEN
|
Neovius, M
|
|
2006
|
9 |
6 |
p. A231-
1 p.
|
artikel
|
| 297 |
PDB9 THE ECONOMIC BENEFIT OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN TYPE 2 NON INSULIN TREATED DIABETES PATIENTS IN SWITZERLAND
|
Holm, MV
|
|
2006
|
9 |
6 |
p. A226-
1 p.
|
artikel
|
| 298 |
PDB33 THE EFFICACY OF INSULIN GLARGINE COMPARED TO OTHER INJECTABLE THERAPIES-A META-ANALYSIS OF CLINICAL OUTCOMES IN INSULIN NAÏVE TYPE 2 DIABETES PATIENTS
|
Pascoe, K
|
|
2006
|
9 |
6 |
p. A234-
1 p.
|
artikel
|
| 299 |
PDB8 THE IMPACT OF IMPROVED BETA-CELL FUNCTION ON MODELLING THE COST-EFFECTIVENESS OF ROSIGLITAZONE IN THE MANAGEMENT OF TYPE 2 DIABETES IN SPAIN
|
Shearer, A
|
|
2006
|
9 |
6 |
p. A226-
1 p.
|
artikel
|
| 300 |
PDB39 THE IMPACT ON QUALITY OF LIFE BY CONVERTING THE TREATMENT OF TYPE 2 DIABETIC PATIENTS FROM CONVENTIONAL INSULIN REGIMENT TO ORAL TREATMENT WITH PIOGLITAZONE
|
Greiner, W
|
|
2006
|
9 |
6 |
p. A236-
1 p.
|
artikel
|
| 301 |
PDB20 THERAPY CLASS CONVERSION IN PATIENTS WITH TYPE 2 DIABETES: ECONOMIC EVALUATION OF INSULIN DETEMIR AND NPH
|
Valentine, WJ
|
|
2006
|
9 |
6 |
p. A230-
1 p.
|
artikel
|
| 302 |
PDB7 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 1 DIABETES
|
McEwan, P
|
|
2006
|
9 |
6 |
p. A225-A226
nvt p.
|
artikel
|
| 303 |
PDB13 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 2 DIABETES
|
McEwan, P
|
|
2006
|
9 |
6 |
p. A227-A228
nvt p.
|
artikel
|
| 304 |
PDB36 THE TRANSLATION AND LINGUISTIC VALIDATION OF THE SATISFACTION WITH ORAL ANTI-DIABETIC AGENTS (SOADA) QUESTIONNAIRE
|
Houchin, C
|
|
2006
|
9 |
6 |
p. A235-
1 p.
|
artikel
|
| 305 |
PDB49 TREATMENT SATISFACTION WITH INSULIN GLARGINE AND INSULIN GLULISINE IN DIABETES MELLITUS-EVALUATED IN AN OBSERVATIONAL STUDY IN GERMANY
|
Daikeler, R
|
|
2006
|
9 |
6 |
p. A239-
1 p.
|
artikel
|
| 306 |
PEN2 COST COMPARISON OF HUMAN GROWTH HORMONE DELIVERED VIA PEN DEVICES AND VIAL/SYRINGE IN PEDIATRIC PATIENTS:A BUDGETARY IMPACT MODEL
|
Bazalo, GR
|
|
2006
|
9 |
6 |
p. A240-
1 p.
|
artikel
|
| 307 |
PEN3 COST COMPARISON OF HUMAN GROWTH HORMONE DELIVERED VIA PEN DEVICES VERSUS VIAL/SYRINGE IN ADULT PATIENTS: A BUDGETARY IMPACT MODEL
|
Bazalo, GR
|
|
2006
|
9 |
6 |
p. A240-A241
nvt p.
|
artikel
|
| 308 |
PEN1 DETERMINATION OF THE TOTAL COST OF DIAGNOSTIC PROCEDURE BY FINE NEEDLE ASPIRATION CYTOLOGY IN PATIENTS WITH THYROID NODULES
|
Borget, I
|
|
2006
|
9 |
6 |
p. A240-
1 p.
|
artikel
|
| 309 |
PEN4 EVALUATION OF THE ASSOCIATION BETWEEN THE QUALITY OF LIFE, SOCIAL CLASS AND HEIGHT IN THE GENERAL ADULT UK POPULATION
|
Christensen, T
|
|
2006
|
9 |
6 |
p. A241-
1 p.
|
artikel
|
| 310 |
PEY9 ASSESSMENT OF THE COST-EFFECTIVENESS OF TRAVOPROST VERSUS LATANOPROST, AS SINGLE AGENTS FOR GLAUCOMA TREATMENT IN FRANCE
|
Payet, S
|
|
2006
|
9 |
6 |
p. A368-
1 p.
|
artikel
|
| 311 |
PEY14 BIMATOPROST, LATANOPROST, AND TRAVOPROST FOR THE TREATMENT OF GLAUCOMA:A COST-EFFECTIVENESS ANALYSIS IN SCANDINAVIA USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL
|
Stewart, WC
|
|
2006
|
9 |
6 |
p. A369-A370
nvt p.
|
artikel
|
| 312 |
PEY18 CHANGES IN MEDICAL AND SURGICAL TREATMENTS OF GLAUCOMA BETWEEN 1997 AND 2003 IN FRANCE
|
Baudouin, C
|
|
2006
|
9 |
6 |
p. A371-
1 p.
|
artikel
|
| 313 |
PEY3 COMPARING EFFICACY OF PROSTAGLANDIN ANALOGUES FOR CONTROLLING INTRA-OCULAR PRESSURE (IOP): RESULTS OF A META-ANALYSIS
|
Mimaud, V
|
|
2006
|
9 |
6 |
p. A366-
1 p.
|
artikel
|
| 314 |
PEY5 COMPARISON OF PHYSICIAN AND PATIENT-REPORTED OUTCOMES OF ADULTS WITH DRY EYE DISEASE (KERATOCONJUNCTIVITIS SICCA) MANAGED OVER TIME IN A PATIENT REGISTRY
|
Steeds, CS
|
|
2006
|
9 |
6 |
p. A367-
1 p.
|
artikel
|
| 315 |
PEY17 COST-EFFECTIVENESS OF PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION: IMPACT OF DIFFERENCES BETWEEN US AND UK HEALTH CARE SYSTEMS
|
Javitt, J
|
|
2006
|
9 |
6 |
p. A370-
1 p.
|
artikel
|
| 316 |
PEY10 COST-EFFECTIVENESS OF TWO TREATMENT SEQUENCES IN GLAUCOMA TREATMENT: XALATAN®-XALACOM® VERSUS TRAVATAN®-DUOTRAV®
|
Maurel, F
|
|
2006
|
9 |
6 |
p. A368-
1 p.
|
artikel
|
| 317 |
PEY16 COST-UTILITY ANALYSIS FOR PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION IN THE UK: THE IMPACT OF DEMOGRAPHIC AND DISEASE CHARACTERISTICS
|
Wolowacz, S
|
|
2006
|
9 |
6 |
p. A370-
1 p.
|
artikel
|
| 318 |
PEY27 DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT SATISFACTION WITH EYE DROPS IN OCULAR HYPERTENSION AND GLAUCOMA
|
Berdeaux, G
|
|
2006
|
9 |
6 |
p. A373-A374
nvt p.
|
artikel
|
| 319 |
PEY4 EFFECTIVENESS OF BRIMONIDINE VERSUS BRINZOLAMIDE IN TREATMENT OF GLAUCOMA: AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE
|
Berdeaux, G
|
|
2006
|
9 |
6 |
p. A366-A367
nvt p.
|
artikel
|
| 320 |
PEY2 EFFECTIVENESS OF TRAVOPROST VERSUS DORZOLAMIDE + TIMOLOL FIXED COMBINATION IN FIRST LINE TREATMENT OF GLAUCOMA:ANALYZED FROM THE UK GENERAL PRACTITIONER RESEARCH DATABASE
|
Berdeaux, G
|
|
2006
|
9 |
6 |
p. A366-
1 p.
|
artikel
|
| 321 |
PEY25 HEALTH-RELATED QUALITY-OF-LIFE AND UTILITY IN DUTCH GLAUCOMA PATIENTS
|
Van Gestel, A
|
|
2006
|
9 |
6 |
p. A373-
1 p.
|
artikel
|
| 322 |
PEY21 IMPACT OF BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND RELATED VISUAL IMPAIRMENT ON PATIENTS' QUALITY OF LIFE AND FUNCTIONING: A SURVEY OF FIVE COUNTRIES
|
Xu, X
|
|
2006
|
9 |
6 |
p. A371-A372
nvt p.
|
artikel
|
| 323 |
PEY13 LAST STAGE GLAUCOMA IN EUROPE: COSTS AND QUALITY OF LIFE OF PATIENTS FROM 4 COUNTRIES
|
Aagren, M
|
|
2006
|
9 |
6 |
p. A369-
1 p.
|
artikel
|
| 324 |
PEY15 LATANOPROST VERSUS TIMOLOL MONOTHERAPY FOR THE TREATMENT OF GLAUCOMA:A COST-EFFECTIVNESS ANALYSIS IN SCANDINAVIA AND THE UK USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL
|
Stewart, WC
|
|
2006
|
9 |
6 |
p. A370-
1 p.
|
artikel
|
| 325 |
PEY20 MEASURING CURRENT USE OF OCULAR HYPOTENSIVE THERAPIES: ACCOUNTING FOR RESTART RATES
|
Schwartz, GF
|
|
2006
|
9 |
6 |
p. A371-
1 p.
|
artikel
|
| 326 |
PEY22 MEDICATION ADHERENCE AND HEALTH CARE COSTS WITH INTRODUCTION OF LATANOPROST THERAPY FOR GLAUCOMA IN A MEDICARE MANAGED CARE POPULATION
|
Bhosle, MJ
|
|
2006
|
9 |
6 |
p. A372-
1 p.
|
artikel
|
| 327 |
PEY24 METRIC PROPERTIES OF THE MACDQOL IN FRENCH, GERMAN, ITALIAN, AND AMERICAN POPULATIONS: AN INDIVIDUALISED QOL INSTRUMENT SPECIFIC TO MACULAR DISEASE (MD)
|
Berdeaux, G
|
|
2006
|
9 |
6 |
p. A372-A373
nvt p.
|
artikel
|
| 328 |
PEY11 MODELING THE COST AND CONSEQUENCES OF RESTOR®, A MULTIFOCAL INTRAOCULAR LENS (IOL) IN REFRACTIVE SURGERY IN FRANCE
|
Berdeaux, G
|
|
2006
|
9 |
6 |
p. A368-A369
nvt p.
|
artikel
|
| 329 |
PEY12 MODELING THE COSTS AND CONSEQUENCES OF RESTOR®, A MULTIFOCAL INTRAOCULAR LENS (IOL), AFTER CATARACT SURGERY IN FRANCE
|
Berdeaux, G
|
|
2006
|
9 |
6 |
p. A369-
1 p.
|
artikel
|
| 330 |
PEY7 MODELLING THE HEALTH ECONOMIC IMPACT OF OLOPATADINE COMPARED TO BRANDED AND GENERIC SODIUM CROMOGLYCATE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN THE UK
|
Smith, AF
|
|
2006
|
9 |
6 |
p. A367-
1 p.
|
artikel
|
| 331 |
PEY6 POSTERIOR CAPSULAR OPACIFICATION AND ND: YAG LASER TREATMENT AFTER CATARACT SURGERY IN FRANCE: COMPARISON ACCORDING TO INTRAOCULAR LENS WITH SQUARE EDGED OPTIC DESIGN
|
Smith, AF
|
|
2006
|
9 |
6 |
p. A367-
1 p.
|
artikel
|
| 332 |
PEY19 PROSTAGLANDIN AGONIST USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMA: A CANADIAN POPULATION BASED ANALYSIS
|
Iskedjian, M
|
|
2006
|
9 |
6 |
p. A371-
1 p.
|
artikel
|
| 333 |
PEY1 USE OF BAYESIAN NETWORKS TO SPECIFY THE NOCTURNAL INTRA-OCULAR PRESSURE PEAK FROM DAYTIME MEASUREMENTS IN GLAUCOMA PATIENTS
|
Nordmann, JP
|
|
2006
|
9 |
6 |
p. A365-A366
nvt p.
|
artikel
|
| 334 |
PEY26 VISION BENEFIT FROM MULTI-FOCAL INTRAOCULAR LENS (IOL) AFTER CATARACT SURGERY ESTIMATED BY PRINCIPAL COMPONENTS ANALYSIS
|
Berdeaux, G
|
|
2006
|
9 |
6 |
p. A373-
1 p.
|
artikel
|
| 335 |
PEY23 VISION WITH RESTOR® VERSUS MONOFOCAL INTRAOCULAR LENSES (IOL) AFTER CATARACT SURGERY: RESULTS OF A POOLED ANALYSIS
|
Berdeaux, G
|
|
2006
|
9 |
6 |
p. A372-
1 p.
|
artikel
|
| 336 |
PEY8 WHEN IS IT COST-EFFECTIVE TO TREAT OCULAR HYPERTENSION? RESULTS OF A DECISION-ANALYTIC HEALTH ECONOMIC MODEL
|
Stewart, WC
|
|
2006
|
9 |
6 |
p. A368-
1 p.
|
artikel
|
| 337 |
PGI19 A COMMUNITY PERSPECTIVE ON THE EFFECT OF GASTROESOPHAGEAL REFLUX DISEASE ON PRODUCTIVITY WHILE AT WORK IN FRANCE
|
Wahlqvist, P
|
|
2006
|
9 |
6 |
p. A247-
1 p.
|
artikel
|
| 338 |
PGI16 ARE ADULTS MORE AVERSE TO TREATMENT RISKS FOR THEIR CHILDREN THAN THEY ARE FOR THEMSELVES?
|
Johnson, FR
|
|
2006
|
9 |
6 |
p. A246-
1 p.
|
artikel
|
| 339 |
PGI14 COMPARATIVE EFFICACY OF PARIET (RABEPRAZOLE): LESSONS FROM CLAIMS DATA
|
Glass, JR
|
|
2006
|
9 |
6 |
p. A245-
1 p.
|
artikel
|
| 340 |
PGI8 COST-EFFECTIVENESS ANALYSIS OF ROTAVIRUS VACCINATION PROGRAMME IN THE UK
|
Largeron, N
|
|
2006
|
9 |
6 |
p. A243-A244
nvt p.
|
artikel
|
| 341 |
PGI7 COST-EFFECTIVENESS OF A POTENTIAL FUTURE HELICOBACTER PYLORI VACCINE IN THE NETHERLANDS
|
De Vries, R
|
|
2006
|
9 |
6 |
p. A243-
1 p.
|
artikel
|
| 342 |
PGI10 COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN GERMANY
|
Wahlqvist, P
|
|
2006
|
9 |
6 |
p. A244-
1 p.
|
artikel
|
| 343 |
PGI17 DEPICTION OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) PREVALENCE IN PRIMARY CARE IN GREECE
|
Papatheodoridis, G
|
|
2006
|
9 |
6 |
p. A246-
1 p.
|
artikel
|
| 344 |
PGI18 DISCRIMINANT VALIDITY OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE IN PATIENTS WITH CROHN'S DISEASE
|
Reilly, MC
|
|
2006
|
9 |
6 |
p. A246-A247
nvt p.
|
artikel
|
| 345 |
PGI13 ECONOMIC EVALUATION OF THE ARTIFICIAL LIVER SUPPORT SYSTEM MARS IN PATIENTS WITH ACUTE-ONCHRONIC LIVER FAILURE-FINAL RESULTS OF A CLINICAL COHORT TRIAL
|
Hessel, FP
|
|
2006
|
9 |
6 |
p. A245-
1 p.
|
artikel
|
| 346 |
PGI11 ECONOMIC EVALUATION OF THE PHARMACOLOGICAL THERAPY OF BLEEDING ESOPHAGEAL VARICES IN MEXICO
|
Garcia-Contreras, F
|
|
2006
|
9 |
6 |
p. A244-
1 p.
|
artikel
|
| 347 |
PGI3 EFFICACY OF ESOMEPRAZOL IN GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD) IN A MEXICAN POPULATION
|
Ballesteros, A
|
|
2006
|
9 |
6 |
p. A242-
1 p.
|
artikel
|
| 348 |
PGI4 ESOMEPRAZOLE VERSUS OTHER PROTON-PUMP INHIBITORS (PPI): CLINICAL AND COST EFFECTIVENESS ANALYSIS
|
Kaczor, M
|
|
2006
|
9 |
6 |
p. A242-
1 p.
|
artikel
|
| 349 |
PGI9 FIBRIN-COATED COLLAGEN FLEECE PATCHES OR FIBRIN GLUE? CLINICAL OUTCOMES FOLLOWING LIVER RESECTION SHOW NO DIFFERENCES
|
Schön, MR
|
|
2006
|
9 |
6 |
p. A244-
1 p.
|
artikel
|
| 350 |
PGI12 GASTROINTESTINAL COMPLICATIONS INDUCED BY NONSTERIODAL ANTI-INFLAMMATORY DRUGS (NSAID): EPIDEMIOLOGICAL EXTRAPOLATION FOR EUROPE AND ECONOMIC CONSIDERATIONS
|
Sterzel, A
|
|
2006
|
9 |
6 |
p. A245-
1 p.
|
artikel
|
| 351 |
PGI5 GASTROINTESTINAL MEDICATION USE AND COSTS IN HEART TRANSPLANT RECIPIENTS RECEIVING MYCOPHENOLATE MOFETIL
|
Legorreta, AP
|
|
2006
|
9 |
6 |
p. A242-A243
nvt p.
|
artikel
|
| 352 |
PGI15 HEALTH-STATE UTILITIES IN LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
|
McLernon, DJ
|
|
2006
|
9 |
6 |
p. A245-A246
nvt p.
|
artikel
|
| 353 |
PGI1 IS COMBINATION THERAPY OF LAMIVUDINE WITH INTERFERON-ALPHA SUPERIOR TO LAMIVUDINE MONOTHERAPY FOR HBEAG-POSITIVE CHRONIC HEPATITIS B? A META-ANALYSIS OF RANDOMIZED TRIALS
|
Sun, X
|
|
2006
|
9 |
6 |
p. A241-
1 p.
|
artikel
|
| 354 |
PGI2 PROTON PUMP INHIBITORS FOR THE TREATMENT OF REFLUX OESOPHAGITIS: ENDOSCOPIC HEALING RATES FROM A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
|
Edwards, SJ
|
|
2006
|
9 |
6 |
p. A241-A242
nvt p.
|
artikel
|
| 355 |
PGI20 THE ASSOCIATION BETWEEN WORK PRODUCTIVITY AND RESPONSE TO PROTON PUMP INHIBITOR THERAPY IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE
|
Wahlqvist, P
|
|
2006
|
9 |
6 |
p. A247-
1 p.
|
artikel
|
| 356 |
PGI6 THE USE OF BUDGET IMPACT MODELLING TO ASSESS THE ECONOMIC CONSEQUENCE OF CHANGING THE PRESCRIPTION PATTERN OF PROTON PUMP INHIBITORS (PPI) IN SWEDEN
|
Hjelmgren, J
|
|
2006
|
9 |
6 |
p. A243-
1 p.
|
artikel
|
| 357 |
PHM1 COST-EFFECTIVENESS OF REGULAR CONTINUOUS PROPHYLACTIC TREATMENT IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A
|
Monzini, MS
|
|
2006
|
9 |
6 |
p. A247-A248
nvt p.
|
artikel
|
| 358 |
PHM11 DEVELOPMENT AND SCORING OF THE SATISFACTION WITH IRON CHELATION THERAPY INSTRUMENT FOR PATIENTS WITH IRON OVERLOAD
|
Rofail, D
|
|
2006
|
9 |
6 |
p. A251-
1 p.
|
artikel
|
| 359 |
PHM7 DIRECT COST OF BETA THALASSEMIA MAJOR: RESUTS FROM THE ITHACA STUDY
|
Mantovani, LG
|
|
2006
|
9 |
6 |
p. A249-A250
nvt p.
|
artikel
|
| 360 |
PHM5 ECONOMIC ANALYSIS OF SURGICAL INTERVENTIONS IN ROMANIAN HAEMOPHILIACS
|
Mihailov, MD
|
|
2006
|
9 |
6 |
p. A249-
1 p.
|
artikel
|
| 361 |
PHM3 HEPARIN-RELATED THROMBOCYTOPENIA ASSOCIATED WITH MAJOR INCREASE IN HOSPITAL COSTS
|
Eisenstein, EL
|
|
2006
|
9 |
6 |
p. A248-
1 p.
|
artikel
|
| 362 |
PHM8 INDIRECT COSTS OF BETA THALASSEMIA MAJOR: RESULTS FROM THE ITACA STUDY
|
Krol, M
|
|
2006
|
9 |
6 |
p. A250-
1 p.
|
artikel
|
| 363 |
PHM2 INPATIENT RESOURCE USE AND COSTS OF TRAUMA IN PATIENTS WITH VS WITHOUT BLOOD TRANSFUSION: EVIDENCE FROM THE HEALTH CARE COST AND UTILIZATION PROJECT DATABASE
|
Boulanger, L
|
|
2006
|
9 |
6 |
p. A248-
1 p.
|
artikel
|
| 364 |
PHM14 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT): A DISCRETE CHOICE EXERCISE
|
Monzini, MS
|
|
2006
|
9 |
6 |
p. A252-
1 p.
|
artikel
|
| 365 |
PHM12 PHYSICIANS' PREFERENCES TOWARD COAGULATION FACTOR CONCENTRATES IN THE TREATMENT OF HEMOPHILIA PATIENTS WITH INHIBITORS: A DISCRETE CHOICE EXPERIMENT
|
Lee, WC
|
|
2006
|
9 |
6 |
p. A251-
1 p.
|
artikel
|
| 366 |
PHM10 QUALITY OF LIFE IN PATIENTS WITH BETA THALASSEMIA MAJOR: RESULTS FROM THE ITHACA STUDY
|
Mantovani, LG
|
|
2006
|
9 |
6 |
p. A250-A251
nvt p.
|
artikel
|
| 367 |
PHM13 SATISFACTION WITH IRON CHELATION THERAPY AND ITS IMPACT ON ADHERENCE IN PATIENTS WITH BETA THALASSEMIA MAJOR: RESULTS FROM THE ITHACA STUDY
|
Rofail, D
|
|
2006
|
9 |
6 |
p. A251-A252
nvt p.
|
artikel
|
| 368 |
PHM6 SOCIETAL COSTS OF ALLOGENEIC BLOOD TRANSFUSION IN THE NETHERLANDS
|
Van Hulst, M
|
|
2006
|
9 |
6 |
p. A249-
1 p.
|
artikel
|
| 369 |
PHM4 SYSTEMATIC REVIEW OF THE COSTS OF HEMATOLOGIC ADVERSE EVENTS IN ADULT CANCER PATIENTS TREATED WITH CHEMOTHERAPY
|
Stephens, JM
|
|
2006
|
9 |
6 |
p. A248-A249
nvt p.
|
artikel
|
| 370 |
PHM9 THE EVALUATION OF ECONOMIES OF SCOPE IN GENETIC SCREENING BY DNA TECHNOLOGY: A MODELING STUDY
|
Rogowski, W
|
|
2006
|
9 |
6 |
p. A250-
1 p.
|
artikel
|
| 371 |
PHP21 ANALYSIS OF COST OF ILLNESS IN THE NETHERLANDS IN 2003: INTEGRATING NATIONAL AND INTERNATIONAL PERSPECTIVES ON HEALTH CARE COSTS
|
Slobbe, LCJ
|
|
2006
|
9 |
6 |
p. A214-
1 p.
|
artikel
|
| 372 |
PHP41 AN ASSESMENT OF TWO IRANIAN SOCIAL SECURITY ORGANIZATION HOSPITALS PERFORMANCE BASED ON THE EFQM MODEL
|
Maleki, MR
|
|
2006
|
9 |
6 |
p. A220-
1 p.
|
artikel
|
| 373 |
PHP8 ANTIBIOTIC UTILIZATION IN NIS REGION OF SERBIA AND MONTENEGRO
|
Kodela, B
|
|
2006
|
9 |
6 |
p. A210-
1 p.
|
artikel
|
| 374 |
PHP30 ASSESSING THE ECONOMIC AND SAFETY IMPACT OF GLASS VERSUS POLYMER CONTAINERS IN A RADIOLOGY DEPARTMENT
|
Gricar, JA
|
|
2006
|
9 |
6 |
p. A216-A217
nvt p.
|
artikel
|
| 375 |
PHP4 ASSESSING THERAPEUTIC IMPROVEMENT IN CANADA AND FRANCE: A COMPARISON OF PMPRB AND ASMR CLASSIFICATIONS
|
Palmer, WN
|
|
2006
|
9 |
6 |
p. A209-
1 p.
|
artikel
|
| 376 |
PHP7 A SURVEY OF UK HEALTH CARE WORKERS' VIEWS ON THE USE OF HANDHELD COMPUTERS IN EVIDENCE-BASED CLINICAL PRACTICE
|
Dickson, AJ
|
|
2006
|
9 |
6 |
p. A210-
1 p.
|
artikel
|
| 377 |
PHP16 ATTITUDES TOWARD HOME CARE AMONG ACUTELY HOSPITALIZED PATIENTS IN HUNGARY
|
Betlehem, J
|
|
2006
|
9 |
6 |
p. A212-
1 p.
|
artikel
|
| 378 |
PHP13 BENEFIT INCIDENCE ANALYSIS BEFORE AND AFTER UNIVERSAL COVERAGE IN THAILAND
|
Prakongsai, P
|
|
2006
|
9 |
6 |
p. A211-A212
nvt p.
|
artikel
|
| 379 |
PHP40 COST-EFFECTIVENESS STUDY OF ADJUSTED CLINICAL GROUPS TO ASSESS THE ABILITY OF SPANISH PRIMARY CARE TEAMS TO BRING ISSUES TO RESOLUTION
|
Serrat, J
|
|
2006
|
9 |
6 |
p. A219-A220
nvt p.
|
artikel
|
| 380 |
PHP1 DESTINATION: FOREIGN PROVIDER (MEDICAL TOURISM FOR THE GERMAN PATIENT)
|
Carrera, P
|
|
2006
|
9 |
6 |
p. A208-
1 p.
|
artikel
|
| 381 |
PHP11 DOSE DISPENSED MEDICINE AND ASSOCIATED MEDICINE AND HEALTH CARE COST
|
Søndergaard, B
|
|
2006
|
9 |
6 |
p. A211-
1 p.
|
artikel
|
| 382 |
PHP19 DRUG PRICE INDICES 1980–2005 IN FINLAND
|
Hahl, J
|
|
2006
|
9 |
6 |
p. A213-
1 p.
|
artikel
|
| 383 |
PHP17 EFFICIENCY OF RHEUMATOLOGY HOSPITAL CARE: CHANGES IN THE AVERAGE LENGTH OF STAY IN RHEUMATOLOGY DEPARTMENTS IN HUNGARY
|
Boncz, I
|
|
2006
|
9 |
6 |
p. A212-A213
nvt p.
|
artikel
|
| 384 |
PHP6 ESTIMATION AND COMPARISON OF OSTOMY APPLIANCE COSTS WITH REIMBURSEMENT TARIFFS IN BELGIUM
|
Vanleene, V
|
|
2006
|
9 |
6 |
p. A209-
1 p.
|
artikel
|
| 385 |
PHP39 EVALUATION OF SCIENTIFIC QUALITY OF POSTMARKETING SURVEILLANCE STUDIES IN GERMANY
|
Dietrich, ES
|
|
2006
|
9 |
6 |
p. A219-
1 p.
|
artikel
|
| 386 |
PHP25 EXPENDITURES ON DRUGS IN DEVELOPED EUROPEAN COUNTRIES
|
Praznovcova, L
|
|
2006
|
9 |
6 |
p. A215-
1 p.
|
artikel
|
| 387 |
PHP37 GENERIC COMPETITION: EFFECT ON PRICES AND SUBSTITUTION EFFECTS
|
Engstrom, A
|
|
2006
|
9 |
6 |
p. A218-A219
nvt p.
|
artikel
|
| 388 |
PHP38 HEALTH TECHNOLOGY ASSESSMENT IN HUNGARY
|
Nádudvari, N
|
|
2006
|
9 |
6 |
p. A219-
1 p.
|
artikel
|
| 389 |
PHP15 IMPACT OF A DRUG POLICY ON AVAILABILITY AND DRUG COST CONTAINMENT IN A TERTIARY CARE HOSPITAL: 10 YEARS OF EXPERIENCE
|
Sharma, S
|
|
2006
|
9 |
6 |
p. A212-
1 p.
|
artikel
|
| 390 |
PHP22 NUTRICORE®: COST-EFFECTIVENESS-ANALYSIS (CE) OF AN EVIDENCE BASED CLINICAL NUTRITION CONCEPT IN CORRELATION WITH RELEVANT CLINICAL OUTCOMES IN HOSPITALIZED MALNOURISHED PATIENTS BY RISKADJUSTMENT OF DIAGNOSIS BASED SEVERITY OF DISEASE
|
Fischer, FJ
|
|
2006
|
9 |
6 |
p. A214-
1 p.
|
artikel
|
| 391 |
PHP33 OCCUPATIONAL INJURIES: USE AND COST OF EMERGENCY DEPARTMENT FOR TREATMENT OF ACCIDENTAL HYPODERMIC NEEDLE PUNCTURES
|
O'Brien, JA
|
|
2006
|
9 |
6 |
p. A217-A218
nvt p.
|
artikel
|
| 392 |
PHP32 PATIENT SATISFACTION WITH THE PHARMACY FIRST MINOR AILMENTS SCHEME
|
Pumtong, S
|
|
2006
|
9 |
6 |
p. A217-
1 p.
|
artikel
|
| 393 |
PHP29 PHARMACEUTICAL BUDGET ALLOCATION: A CAPITATION MODEL
|
Gilabert i Perramon, A
|
|
2006
|
9 |
6 |
p. A216-
1 p.
|
artikel
|
| 394 |
PHP36 PHARMACOEPIDEMIOLOGICAL ANALYSIS OF THE USEING DRUGS FROM REIMBESMENT LIST IN RUSSIA
|
Yagudina, RI
|
|
2006
|
9 |
6 |
p. A218-
1 p.
|
artikel
|
| 395 |
PHP34 PHYSICIANS' ATTITUDES TO AND EXPERIENCE WITH INCREASED USE OF INDIVIDUAL REIMBURSEMENT VERSUS GENERAL REIMBURSEMENT OF NEW IMPORTANT PHARMACEUTICALS
|
Levorsen, A
|
|
2006
|
9 |
6 |
p. A218-
1 p.
|
artikel
|
| 396 |
PHP28 PILOT STUDY OF THE IMPACT OF NEW PRICING SCHEMA ON DRUG PRICES IN REPUBLIC SERBIA
|
Markovic, AB
|
|
2006
|
9 |
6 |
p. A216-
1 p.
|
artikel
|
| 397 |
PHP10 POTENTIAL IMPACT OF HOSPITAL DISCHARGE PRESCRIPTIONS ON COMMUNITY PRESCRIBING-AN IRISH PERSPECTIVE
|
Usher, C
|
|
2006
|
9 |
6 |
p. A210-A211
nvt p.
|
artikel
|
| 398 |
PHP18 PRICES OF GENERIC DRUGS IN FINLAND VS. EUROPE
|
Bergius, S
|
|
2006
|
9 |
6 |
p. A213-
1 p.
|
artikel
|
| 399 |
PHP3 PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN ITALY
|
Lopatriello, S
|
|
2006
|
9 |
6 |
p. A208-A209
nvt p.
|
artikel
|
| 400 |
PHP2 RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AND OUT-OF-POCKET COSTS
|
Bhandari, A
|
|
2006
|
9 |
6 |
p. A208-
1 p.
|
artikel
|
| 401 |
PHP14 STAKEHOLDERS' PERSPECTIVES ON IMPROVING ACCESS TO PRIMARY CARE
|
Pumtong, S
|
|
2006
|
9 |
6 |
p. A212-
1 p.
|
artikel
|
| 402 |
PHP26 SUPPLY SIDE COST-CONTAINMENT IN GERMANY: WIN SOME, LOSE SOME
|
Carrera, P
|
|
2006
|
9 |
6 |
p. A215-
1 p.
|
artikel
|
| 403 |
PHP20 SWITCH PATTERNS AROUND PATENT EXPIRY WITH ECONOMIC IMPLICATIONS FOR THE NETHERLANDS
|
Boersma, C
|
|
2006
|
9 |
6 |
p. A213-A214
nvt p.
|
artikel
|
| 404 |
PHP35 TELEMEDICINE IN THE U.S. MEDICARE PROGRAM: 2007 REIMBURSEMENT IMPLICATIONS
|
Pierce, CA
|
|
2006
|
9 |
6 |
p. A218-
1 p.
|
artikel
|
| 405 |
PHP27 THE ANALYSIS OF TEMPORARY WORK DISABILITY FOR THE PERIOD OF OVER 30 DAYS IN THE REPUBLIC OF SERBIA
|
Perovich, S
|
|
2006
|
9 |
6 |
p. A215-A216
nvt p.
|
artikel
|
| 406 |
PHP24 THE COST OF ILLNESS: SPAIN 1980–2000
|
Gisbert, R
|
|
2006
|
9 |
6 |
p. A215-
1 p.
|
artikel
|
| 407 |
PHP31 THE ECONOMIC EVALUATION OF HOME PHARMACIES IN HEALTH AREA
|
García-Ruiz, A
|
|
2006
|
9 |
6 |
p. A217-
1 p.
|
artikel
|
| 408 |
PHP5 THE PHARMACEUTICAL INDUSTRY PERSPECTIVE ON PHARMACOECONOMICS IN SAUDI ARABIA
|
Alsultan, M
|
|
2006
|
9 |
6 |
p. A209-
1 p.
|
artikel
|
| 409 |
PHP23 TIME SERIES ANALYSIS OF PHARMACEUTICAL PUBLIC EXPENDITURE: EVALUATION OF SUPPLY MEASURES
|
Magem Luque, D
|
|
2006
|
9 |
6 |
p. A214-A215
nvt p.
|
artikel
|
| 410 |
PHP9 USE OF ANTIBIOTICS AT CLINICAL CENTRE OF MONTENEGRO
|
Goranovic, S
|
|
2006
|
9 |
6 |
p. A210-
1 p.
|
artikel
|
| 411 |
PHP12 WASTAGE OF MEDICINES IN PORTUGAL
|
Crisóstomo, S
|
|
2006
|
9 |
6 |
p. A211-
1 p.
|
artikel
|
| 412 |
PIH17 ASSESSING PSYCHOLOGICAL BURDEN AND TREATMENT BENEFITS IN PEDIATRIC PATIENTS WITH BEDWETTING
|
Weinstein, D
|
|
2006
|
9 |
6 |
p. A257-
1 p.
|
artikel
|
| 413 |
PIH1 BUDGET IMPACT ANALYSIS OF AVODART (DUTASTERIDE) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN POLAND
|
Dardzinski, W
|
|
2006
|
9 |
6 |
p. A252-
1 p.
|
artikel
|
| 414 |
PIH20 CONJOINT-ANALYSIS QALYS FOR ACUTE CONDITIONS
|
Johnson, FR
|
|
2006
|
9 |
6 |
p. A258-
1 p.
|
artikel
|
| 415 |
PIH5 COST-EFFECTIVENESS OF DUTASTERIDE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
|
Kaczor, M
|
|
2006
|
9 |
6 |
p. A253-A254
nvt p.
|
artikel
|
| 416 |
PIH7 COST-EFFECTIVENESS OF SINGLE-EMBRYO-TRANSFER (SET) VERSUS DOUBLE-EMBRYO-TRANSFER (DET) STRATEGIES IN IN-VITRO FERTILIZATION
|
Poulsen, PB
|
|
2006
|
9 |
6 |
p. A254-
1 p.
|
artikel
|
| 417 |
PIH14 DETECTION OF SEMANTIC AMBIGUITY IN THE ITALIAN CHILD-FRIENDLY EQ-5D VERSION
|
Tomasetto, C
|
|
2006
|
9 |
6 |
p. A256-A257
nvt p.
|
artikel
|
| 418 |
PIH15 DEVELOPMENT OF AN ICIQ NOCTURNAL ENURESIS QOL QUESTIONNAIRE
|
Holm-Larsen, T
|
|
2006
|
9 |
6 |
p. A257-
1 p.
|
artikel
|
| 419 |
PIH18 DIMENSIONS OF HRQOL AND SATISFACTION WITH LIFE IMPROVE IN ED PATIENTS SWITCHING FROM OTHER ORAL ED MEDICATION TO TADALAFIL
|
Taipale, K
|
|
2006
|
9 |
6 |
p. A257-A258
nvt p.
|
artikel
|
| 420 |
PIH6 ECONOMIC EVALUATION OF CARBETOCINE FOR THE PREVENTION OF UTERINE ATONY IN PATIENTS WITH RISK FACTORS IN MEXICO
|
Del Angel García, G
|
|
2006
|
9 |
6 |
p. A254-
1 p.
|
artikel
|
| 421 |
PIH23 ERECTILE DYSFUNCTION IN SPAIN: CLINICAL RESPONSE TO TREATMENTS
|
Gutiérrez del Pozo, R
|
|
2006
|
9 |
6 |
p. A259-
1 p.
|
artikel
|
| 422 |
PIH19 ESTIMATING UTILITY IN ROTAVIRUS GASTROENTERITIS IN CHILDREN UNDER FIVE IN THE UK
|
Martin, A
|
|
2006
|
9 |
6 |
p. A258-
1 p.
|
artikel
|
| 423 |
PIH11 EXPENDITURES ON PHARMACEUTICALS: DEMOGRAPHIC CHANGE AND INNOVATION-AN EMPIRICAL ANALYSIS
|
Ilgin, Y
|
|
2006
|
9 |
6 |
p. A255-A256
nvt p.
|
artikel
|
| 424 |
PIH2 HEALTH ECONOMIC CONSEQUENCES OF THE CHOICE OF FOLLICLE STIMULATING HORMONE ALTERNATIVES IN IVF TREATMENT
|
Poulsen, PB
|
|
2006
|
9 |
6 |
p. A252-A253
nvt p.
|
artikel
|
| 425 |
PIH21 INFLUENCE OF CONCOMITANT DISEASES ON THE CLINICAL RESPONSE TO TREATMENT FOR ERECTILE DYSFUNCTION
|
Gutiérrez del Pozo, R
|
|
2006
|
9 |
6 |
p. A258-A259
nvt p.
|
artikel
|
| 426 |
PIH22 LINGUISTIC VALIDATION OF THE MENSTRUAL DISTRESS QUESTIONNAIRE (MDQ) IN AN INTERNATIONAL STUDY FOR A NEW COMBINED ORAL CONTRACEPTIVE PILL
|
Fernandez, N
|
|
2006
|
9 |
6 |
p. A259-
1 p.
|
artikel
|
| 427 |
PIH13 PHARMACOECONOMIC ASPECTS OF REFORMS OF PHARMACEUTICAL SECTOR: MONTENEGRO EXPERIENCE
|
Bralic, R
|
|
2006
|
9 |
6 |
p. A256-
1 p.
|
artikel
|
| 428 |
PIH24 PREFERENCES IN ITALIAN BPH PATIENTS
|
Arpinelli, F
|
|
2006
|
9 |
6 |
p. A259-
1 p.
|
artikel
|
| 429 |
PIH8 PROPORTION OF HERPES ZOSTER (HZ) PATIENTS DEVELOPING POST-HERPETIC NEURALGIA (PHN) AND ITS MANAGEMENT IN THE UK
|
Gauthier, A
|
|
2006
|
9 |
6 |
p. A254-A255
nvt p.
|
artikel
|
| 430 |
PIH10 SERVICE UTILIZATION AND HEALTH CARE COSTS OF THE ELDERLY POPULATION IN GERMANY
|
Heinrich, S
|
|
2006
|
9 |
6 |
p. A255-
1 p.
|
artikel
|
| 431 |
PIH4 THE COST EFFECTIVENESS OF IVF IN ITALY: IMPLICATIONS OF A NEW LAW
|
Dale, PL
|
|
2006
|
9 |
6 |
p. A253-
1 p.
|
artikel
|
| 432 |
PIH25 THE COUPLE-PROJECT: POOLED ANALYSIS OF SATISFACTION WITH VARDENAFIL TREATMENT IN MEN WITH ERECTILE DYSFUNCTION AND THEIR PARTNERS
|
Evers, T
|
|
2006
|
9 |
6 |
p. A259-A260
nvt p.
|
artikel
|
| 433 |
PIH12 THE DETERMINANTS OF DRUGS PRESCRIPTION FOR CHILDREN IN GENERAL PRACTICE
|
Franc, C
|
|
2006
|
9 |
6 |
p. A256-
1 p.
|
artikel
|
| 434 |
PIH9 THE ECONOMIC BURDEN OF DRUGS FOR CHILDREN CARE IN GENERAL PRACTICE: AN OBSERVATIONAL STUDY IN FRANCE
|
Pelletier-Fleury, N
|
|
2006
|
9 |
6 |
p. A255-
1 p.
|
artikel
|
| 435 |
PIH16 TREATMENT DURATION FOR ATROPHIC VAGINITIS: CLINICAL TRIALS VERSUS “THE REAL WORLD”
|
Balu, S
|
|
2006
|
9 |
6 |
p. A257-
1 p.
|
artikel
|
| 436 |
PIH3 VACCINATION WITH RIX4414 IS COST-EFFECTIVE IN A BELGIAN SETTING
|
Fruytier, A
|
|
2006
|
9 |
6 |
p. A253-
1 p.
|
artikel
|
| 437 |
PIN2 A COST-BENEFIT ANALYSIS OF DIFFERENT VARICELLA VACCINATION STRATEGIES INVOLVING ITALIAN CHILDREN AND ADOLESCENTS
|
Marocco, A
|
|
2006
|
9 |
6 |
p. A299-
1 p.
|
artikel
|
| 438 |
PIN16 AN OBSERVATIONAL HEALTH-ECONOMIC ANALYSIS OF THE TREATMENT OF PATIENTS WITH VORICONAZOLE IN A REAL LIFE SETTING
|
Van Campenhout, H
|
|
2006
|
9 |
6 |
p. A303-A304
nvt p.
|
artikel
|
| 439 |
PIN4 ANTIBIOTIC THERAPY OF NOSOCOMIAL INFECTION IN THE INTENSIVE CARE UNIT: A COST-EFFECTIVENESS ANALYSIS
|
Kulikov, A
|
|
2006
|
9 |
6 |
p. A299-
1 p.
|
artikel
|
| 440 |
PIN15 CHRONIC HEPATITIS B (CHB) MANAGEMENT COSTS IN SWEDEN
|
De Cock, E
|
|
2006
|
9 |
6 |
p. A303-
1 p.
|
artikel
|
| 441 |
PIN1 CLINICAL AND ECONOMIC IMPACT OF INTRODUCING A QUADRIVALENT (6, 11, 16, 18) HUMAN PAPILLOMAVIRUS VACCINE IN SWITZERLAND
|
Gerber, S
|
|
2006
|
9 |
6 |
p. A298-A299
nvt p.
|
artikel
|
| 442 |
PIN21 COST-BENEFIT ANALYSIS OF VACCINATION PROGRAMME AGAINST POLIOMYELITIS IN MALAYSIA: ORAL POLIO VACCINE (OPV) VS INACTIVATED POLIO VACCINE (IPV)
|
Aljunid, S
|
|
2006
|
9 |
6 |
p. A305-
1 p.
|
artikel
|
| 443 |
PIN9 COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) AND RIBAVIRIN (COPEGUS) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) CO-INFECTION
|
Rubio Terres, C
|
|
2006
|
9 |
6 |
p. A301-
1 p.
|
artikel
|
| 444 |
PIN8 COST-EFFECTIVENESS OF INTERVENTIONS ENSURING BLOOD TRANSFUSION SAFETY IN AFRICA
|
van Hulst, M
|
|
2006
|
9 |
6 |
p. A301-
1 p.
|
artikel
|
| 445 |
PIN19 COST-EFFECTIVENESS OF MASS VACCINATION WITH A ROTAVIRUS VACCINE IN THE NETHERLANDS
|
Al, MJ
|
|
2006
|
9 |
6 |
p. A304-
1 p.
|
artikel
|
| 446 |
PIN11 COST-EFFECTIVENESS OF OSELTAMIVIR FOR THE TREATMENT OF INFLUENZA IN ADULTS AND CHILDREN IN FINLAND
|
Järvinen, A
|
|
2006
|
9 |
6 |
p. A302-
1 p.
|
artikel
|
| 447 |
PIN10 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) FOR THE TREATMENT OF CHRONIC HEPATITIS B IN ITALY
|
Eandi, M
|
|
2006
|
9 |
6 |
p. A301-A302
nvt p.
|
artikel
|
| 448 |
PIN3 COST–EFFECTIVNESS ANALYSIS OF TONSILOPHARYNGITIS AND RHYNOPHARINGITIS ACCUTA, ANTIBIOTIC TREATMANT, SRBIJA, NIS REGION
|
Mihajlovic, MM
|
|
2006
|
9 |
6 |
p. A299-
1 p.
|
artikel
|
| 449 |
PIN12 COST MINIMALISATION ANALYSIS OF AVERAGE ACUTE HOSPITAL INFECTIONS TREATMENT WITH TARGOCID (TEICOPLANIN) OR VANCOMYCINE FROM SERVICEPROVIDER PERSPECTIVE IN POLAND
|
Kawalec, P
|
|
2006
|
9 |
6 |
p. A302-
1 p.
|
artikel
|
| 450 |
PIN20 COSTS AND OUTCOMES OF NOSOCOMIAL PNEUMONIA IN A SAMPLE OF BELGIAN HOSPITALS
|
Spaepen, E
|
|
2006
|
9 |
6 |
p. A305-
1 p.
|
artikel
|
| 451 |
PIN18 COST-UTILITY ANALYSIS OF TREATMENT ALTERNATIVES IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B
|
Sun, X
|
|
2006
|
9 |
6 |
p. A304-
1 p.
|
artikel
|
| 452 |
PIN14 ECONOMIC EVALUATION OF CASPOFUNGIN (CANCIDAS®) VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL THERAPY OF SUSPECTED SYSTEMIC FUNGAL INFECTION IN THE GERMAN HOSPITAL SETTING
|
Kaskel, P
|
|
2006
|
9 |
6 |
p. A303-
1 p.
|
artikel
|
| 453 |
PIN13 ECONOMIC EVALUATION OF EARLY MONOTHERAPY WITH INTERFERON VERSUS DELAYED COMBINATION THERAPY WITH INTERFERON AND RIBAVIRIN IN PATIENTS WITH ACUTE HEPATITIS C
|
Dintsios, CM
|
|
2006
|
9 |
6 |
p. A302-
1 p.
|
artikel
|
| 454 |
PIN27 ECONOMIC MODELLING TO DETERMINE THE COSTEFFECTIVENESS OF TREATMENT OF PATIENTS WITH HISTOLOGICALLY MILD CHRONIC HEPATITIS C WITH PEGYLATED INTERFERON ALPHA-2B PLUS RIBAVIRIN
|
Campbell, S
|
|
2006
|
9 |
6 |
p. A307-
1 p.
|
artikel
|
| 455 |
PIN31 HEALTH RELATED QUALITY OF LIFE IN CHRONIC HEPATITIS B PATIENTS
|
Li, SC
|
|
2006
|
9 |
6 |
p. A308-
1 p.
|
artikel
|
| 456 |
PIN23 INDICATOR OF ANTIBIOTIC USE IN PUBLIC PHARMACY CHAIN BELGRADE
|
Sovtic, DD
|
|
2006
|
9 |
6 |
p. A306-
1 p.
|
artikel
|
| 457 |
PIN28 IS THE PRESCRIBING OF ANTIBIOTICS FOR THE MOST COMMON INFECTIONS IN PRIMARY HEALTH CARE RATIONAL OR NOT?
|
Duborija-Kovacevic, N
|
|
2006
|
9 |
6 |
p. A307-
1 p.
|
artikel
|
| 458 |
PIN25 LONG TERM EFFECT OF WARD PHARMACY CONTROLLED ADMINISTRATION OF ANTIBIOTICS ON ANTIMICROBIAL TREATMENT COSTS
|
Van Hulst, M
|
|
2006
|
9 |
6 |
p. A306-
1 p.
|
artikel
|
| 459 |
PIN6 PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS MORE COST-EFFECTIVE THAN FILGRASTIM IN WOMEN WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN GERMANY
|
Goertz, A
|
|
2006
|
9 |
6 |
p. A300-
1 p.
|
artikel
|
| 460 |
PIN30 PSYCHOMETRIC VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT (AIA) QUESTIONNAIRE IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
|
Wild, D
|
|
2006
|
9 |
6 |
p. A308-
1 p.
|
artikel
|
| 461 |
PIN5 THE COST EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B
|
Kowalik, E
|
|
2006
|
9 |
6 |
p. A300-
1 p.
|
artikel
|
| 462 |
PIN17 THE COST-EFFECTIVENESS OF A MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN GERMANY
|
Carroll, SM
|
|
2006
|
9 |
6 |
p. A304-
1 p.
|
artikel
|
| 463 |
PIN7 THE COST-EFFECTIVENESS OF ENTECAVIR IN THE LONGTERM TREATMENT OF NUCLEOSIDE-NAÏVE AND LAMIVUDINE-REFRACTORY CHRONIC HEPATITIS B PATIENTS IN SWEDEN
|
Cerri, KH
|
|
2006
|
9 |
6 |
p. A300-A301
nvt p.
|
artikel
|
| 464 |
PIN24 THE USE OF ANTIBIOTICS IN CHILDREN POPULATION IN BELGRADE REGION
|
Sovtic, DD
|
|
2006
|
9 |
6 |
p. A306-
1 p.
|
artikel
|
| 465 |
PIN22 TREATMENT PATTERNS AND OUTCOMES ASSOCIATED WITH MULTIDRUG RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS (MRSA) IN CANADIAN TEACHING HOSPITALS: INTERIM ANALYSIS
|
Iskedjian, M
|
|
2006
|
9 |
6 |
p. A305-
1 p.
|
artikel
|
| 466 |
PIN32 VALIDATION OF THE PATIENTS' ATTITUDES AND PERCEPTIONS TOWARDS HAART QUESTIONNAIRE
|
Fumaz, C
|
|
2006
|
9 |
6 |
p. A309-
1 p.
|
artikel
|
| 467 |
PMC9 A REVIEW OF FACTORS AFFECTING THERAPEUTIC COMPLIANCE
|
Jin, J
|
|
2006
|
9 |
6 |
p. A272-A273
nvt p.
|
artikel
|
| 468 |
PMC8 ECONOMIC DECISION MODELLING: CALCULATION OF TOTAL NET MONETARY BENEFITS OF GUIDELINE IMPLEMENTATION INTO CLINICAL PRACTICE
|
Hoomans, T
|
|
2006
|
9 |
6 |
p. A272-
1 p.
|
artikel
|
| 469 |
PMC11 EFFECTIVE USE OF ELECTRONIC DATA CAPTURE (EDC) TO IMPROVE THE QUALITY AND EFFICIENCY OF THE ANALYSIS OF PATIENT REPORTED OUTCOMES
|
Ooms, KL
|
|
2006
|
9 |
6 |
p. A273-
1 p.
|
artikel
|
| 470 |
PMC2 EFFICIENT DATA MINING AND PROBABILISTIC INFERENCE WITH P-COURSE: A BAYESIAN METHOD WITH MULTILEVEL PRIORS FOR MEDICAL APPLICATIONS
|
Soini, EJ
|
|
2006
|
9 |
6 |
p. A270-
1 p.
|
artikel
|
| 471 |
PMC13 EMPIRICAL RESEARCH FOR WILLINGNESSTO PAYFOR ONE QALY GAIN
|
Ohkusa, Y
|
|
2006
|
9 |
6 |
p. A274-
1 p.
|
artikel
|
| 472 |
PMC10 ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING THE SPANISH VERSION OF THE SF-36. IS IT WORTHY TO CALCULATE WEIGHT VALUES FOR UTILITY MEASURES?
|
Rebollo, P
|
|
2006
|
9 |
6 |
p. A273-
1 p.
|
artikel
|
| 473 |
PMC15 HOSPITAL PHARMACY DRUG DELIVERY TIME: A WORK FLOW MANAGEMENT ISSUE
|
Pierce, CA
|
|
2006
|
9 |
6 |
p. A274-
1 p.
|
artikel
|
| 474 |
PMC6 IMPLEMENTING NATURAL HISTORY STUDIES IN EURASIA: THE NIEMANN-PICK EXPERIENCE WITH RAPIDLY CHANGING NATIONAL REGULATIONS
|
Madison, M
|
|
2006
|
9 |
6 |
p. A271-A272
nvt p.
|
artikel
|
| 475 |
PMC5 INDIRECT COSTS OF COMMON COLD IN GERMANY
|
Hessel, FP
|
|
2006
|
9 |
6 |
p. A271-
1 p.
|
artikel
|
| 476 |
PMC14 MEASURING PATIENT-REPORTED SIDE EFFECTS OF DRUGS: ITS IMPORTANCE AND METHODOLOGICAL CHALLENGES
|
Foster, JM
|
|
2006
|
9 |
6 |
p. A274-
1 p.
|
artikel
|
| 477 |
PMC17 MONITORING OF PHARMACEUTICAL COST OF REIMBURSED MEDICINES BY COMBINING OFFICIAL PHARMACY INVOICE DATA WITH COMMERCIAL IMS SALES DATA
|
Van Wilder, P
|
|
2006
|
9 |
6 |
p. A275-
1 p.
|
artikel
|
| 478 |
PMC4 PRESENTING IGNORANCE: A POSSIBILITY INTERVAL APPROACH TO DEPICT HIGH-LEVEL UNCERTAINTY DUE TO CENSORING OR NON-RESPONDENTS
|
Turunen, JH
|
|
2006
|
9 |
6 |
p. A271-
1 p.
|
artikel
|
| 479 |
PMC16 PROPOSED CHANGES TO PHYSICIAN FEE SCHEDULE: 2007 PRACTICE EXPENSE CONCEPTUAL METHODOLOGY
|
Pierce, CA
|
|
2006
|
9 |
6 |
p. A274-A275
nvt p.
|
artikel
|
| 480 |
PMC12 REVIEW ON THE IMPACT OF DOSE FREQUENCY ON COMPLIANCE AND HEALTH OUTCOMES
|
Shi, L
|
|
2006
|
9 |
6 |
p. A273-
1 p.
|
artikel
|
| 481 |
PMC1 SIMULATION MODELING OF CARDIOVASCULAR DISEASE: IS APPLYING AVERAGE LIFE EXPECTANCY TO ALL SURVIVORS DETAILED ENOUGH?
|
Proskorovsky, I
|
|
2006
|
9 |
6 |
p. A270-
1 p.
|
artikel
|
| 482 |
PMC7 THE IMPLICATIONS OF DIFFERING ASSUMPTIONS REGARDING THE BASIS OF PLACEBO RESPONSES ON THE ESTIMATION OF COST-EFFECTIVENESS
|
Hawkins, NS
|
|
2006
|
9 |
6 |
p. A272-
1 p.
|
artikel
|
| 483 |
PMC18 USING DISTANCE LEARNING TO UNDERSTAND DISCRETE EVENT SIMULATION
|
Hunting, B
|
|
2006
|
9 |
6 |
p. A275-
1 p.
|
artikel
|
| 484 |
PMH29 ACUTE HOSPITALIZATION IN THE ELDERLY:RELATIONSHIP WITH PSYCHIATRIC MORBIDITY AND SOCIAL EQUITY IN HEALTH CARE ACESS IN SINGAPORE
|
Ng, TP
|
|
2006
|
9 |
6 |
p. A318-
1 p.
|
artikel
|
| 485 |
PMH38 A MODEL TO ASSESS THE COST-EFFECTIVENESS OF NEW TREATMENTS FOR DEPRESSION
|
Sobocki, P
|
|
2006
|
9 |
6 |
p. A321-
1 p.
|
artikel
|
| 486 |
PMH5 A 3-MONTH ASSESSMENT OF TREATMENT PRESCRIBED TO PATIENTS WITH ADHD AND ITS IMPACT ON CLINICAL SEVERITY AND QOL OUTCOMES ACROSS 10 EUROPEAN COUNTRIES. RESULTS FROM ATTENTION DEFICIT/ HYPERACTIVITY DISODER OBSERVATIONAL RESEARCH IN EUROPE (ADORE)
|
Mata Lorenzo, MJ
|
|
2006
|
9 |
6 |
p. A310-A311
nvt p.
|
artikel
|
| 487 |
PMH32 ANALYSIS OF A MULTINATIONAL, CROSS-SECTIONAL SURVEY OF PHYSICIAN DESCRIPTIONS AND PERCEPTIONS OF PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
|
Leeuwenkamp, O
|
|
2006
|
9 |
6 |
p. A319-
1 p.
|
artikel
|
| 488 |
PMH41 ANXIETY DISORDERS: THE PATIENTS' PERSPECTIVE
|
Wade, AG
|
|
2006
|
9 |
6 |
p. A322-
1 p.
|
artikel
|
| 489 |
PMH40 ASSESSING SELECTION BIAS ON TREATMENT EFFECTS IN OBSERVATIONAL STUDIES WITH REPEATED OUTCOME MEASURES: REGRESSION, PROPENSITY SCORING, FIXEDEFFECTS MODELS, AND BAYESIAN ESTIMATION METHODS
|
Ratcliffe, M
|
|
2006
|
9 |
6 |
p. A322-
1 p.
|
artikel
|
| 490 |
PMH46 ASSESSING THE CROSS-CULTURAL COMPARABILITY OF THE CENTRE FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE (CES-D)
|
Meads, DM
|
|
2006
|
9 |
6 |
p. A324-
1 p.
|
artikel
|
| 491 |
PMH24 ASSESSMENT OF RESOURCE UTILISATION IN ADULTS DIAGNOSED WITH DEPRESSION IN THE UK:A GPRD-BASED STUDY
|
Bineau, S
|
|
2006
|
9 |
6 |
p. A317-
1 p.
|
artikel
|
| 492 |
PMH4 ASSOCIATION BETWEEN CHANGES ON THE NEGATIVE SYMPTOM ASSESSMENT SCALE AND MEASUREES OF FUNCTIONAL OUTCOME IN SCHIZOPHRENIA
|
Leeuwenkamp, O
|
|
2006
|
9 |
6 |
p. A310-
1 p.
|
artikel
|
| 493 |
PMH8 BUDGET IMPACT MODEL FOR DETERMINING THE COSTS OF INTRODUCING ZIPRASIDONE FOR THE MANAGEMENT OF ACUTE BIPOLAR MANIA IN SPAIN
|
Darba, J
|
|
2006
|
9 |
6 |
p. A311-A312
nvt p.
|
artikel
|
| 494 |
PMH37 BURDEN OF ILLNESS OF PATIENTS WITH ANXIETY IN THE UK
|
Makinson, G
|
|
2006
|
9 |
6 |
p. A321-
1 p.
|
artikel
|
| 495 |
PMH16 COST EFFECTIVENESS MODEL COMPARING FAST DISSOLVING OLANZAPINE AND CONVENTIONAL OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA
|
Ozsogut, B
|
|
2006
|
9 |
6 |
p. A314-
1 p.
|
artikel
|
| 496 |
PMH15 COST-EFFECTIVENESS OF AMISULPRID COMPARED TO RISPERIDONE AND OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND
|
Kowalik, E
|
|
2006
|
9 |
6 |
p. A314-
1 p.
|
artikel
|
| 497 |
PMH1 COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): IMPACT OF COEXISTING CONDITIONS
|
Schlander, M
|
|
2006
|
9 |
6 |
p. A309-
1 p.
|
artikel
|
| 498 |
PMH9 COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN FIVE JURISDICTIONS
|
Schlander, M
|
|
2006
|
9 |
6 |
p. A312-
1 p.
|
artikel
|
| 499 |
PMH27 COST-EFFECTIVENESS OF COGNITIVE-BEHAVIOURAL THERAPY (CBT) FOR MENTAL ILLNESS: AN INTERNATIONAL REVIEW
|
Payne, K
|
|
2006
|
9 |
6 |
p. A318-
1 p.
|
artikel
|
| 500 |
PMH13 COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS CITALOPRAM IN OUTPATIENTS SUFFERING FROM MAJOR DEPRESSIVE DISORDER
|
Fantino, B
|
|
2006
|
9 |
6 |
p. A313-
1 p.
|
artikel
|
| 501 |
PMH17 COST-EFFECTIVENESS OF LONG ACTING METHYLPHENIDATE-OROS IN ADHD YOUTHS WITH SUBOPTIMAL SYMPTOM CONTROL ON IMMEDIATE-RELEASE METHYLPHENIDATE IN THE NETHERLANDS
|
Faber, A
|
|
2006
|
9 |
6 |
p. A314-A315
nvt p.
|
artikel
|
| 502 |
PMH21 COST-UTILITY ANALYSIS OF ANTIDEPRESSANTS FOR SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER
|
Malone, DC
|
|
2006
|
9 |
6 |
p. A316-
1 p.
|
artikel
|
| 503 |
PMH45 CROSS-SECTIONAL EVALUATION OF HEALTH STATE UTILITY IN SWEDISH OUTPATIENTS SUFFERING FROM MAJOR DEPRESSIVE DISORDER
|
Eriksson, T
|
|
2006
|
9 |
6 |
p. A323-
1 p.
|
artikel
|
| 504 |
PMH30 DIFFUSION OF NEWLY-APPROVED GENERIC DRUG PRODUCT USE WITHIN A STATE EMPLOYEE PRESCRIPTION DRUG PROGRAM: A COMPARISON OF MAIL ORDER VERSUS RETAIL PHARMACY CLAIMS
|
Johnsrud, M
|
|
2006
|
9 |
6 |
p. A319-
1 p.
|
artikel
|
| 505 |
PMH18 DIRECT COST OF DEPRESSION–ANALYSIS OF A GERMAN CLAIMS DATABASE
|
Gothe, H
|
|
2006
|
9 |
6 |
p. A315-
1 p.
|
artikel
|
| 506 |
PMH10 FUNCTIONAL IMPAIRMENT OF PATIENTS WITH ATTENTIONDEFICIT/ HYPERACTIVITY DISORDER (ADHD): AN ALTERNATIVE COST-EFFECTIVENESS ANALYSIS OF CLINICALLY PROVEN TREATMENT STRATEGIES BASED UPON THE NIMH MTA STUDY
|
Schlander, M
|
|
2006
|
9 |
6 |
p. A312-
1 p.
|
artikel
|
| 507 |
PMH43 IMPACT OF NEGATIVE SYMPTOMS ON FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA IN FIVE EUROPEAN COUNTRIES
|
Leeuwenkamp, O
|
|
2006
|
9 |
6 |
p. A323-
1 p.
|
artikel
|
| 508 |
PMH19 IMPACT OF REMISSION IN MAJOR DEPRESSIVE DISORDER ON ECONOMIC BURDEN OF ILLNESS IN SWEDEN
|
Sobocki, P
|
|
2006
|
9 |
6 |
p. A315-
1 p.
|
artikel
|
| 509 |
PMH34 IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN SCHIZOPHRENIC PATIENTS SWITCHED TO RISPERIDONE LONG-ACTING INJECTION (RLAI)
|
Peuskens, J
|
|
2006
|
9 |
6 |
p. A320-
1 p.
|
artikel
|
| 510 |
PMH47 MEASURING RELAPSE AFTER ADOLESCENT SUBSTANCE ABUSE TREATMENT: A PROPORTIONAL HAZARD APPROACH
|
CieslaR, JR
|
|
2006
|
9 |
6 |
p. A324-
1 p.
|
artikel
|
| 511 |
PMH6 MENTAL HEALTH IN THE FIRST MONTHS OF HEMODIALYSIS AS A PREDICTOR OF SURVIVAL
|
Valdés, C
|
|
2006
|
9 |
6 |
p. A311-
1 p.
|
artikel
|
| 512 |
PMH7 OFF-LABEL UTILIZATION OF METHYLPHENIDATE FOR ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY: INSIGHTS FROM THE NORDBADEN PROJECT
|
Schlander, M
|
|
2006
|
9 |
6 |
p. A311-
1 p.
|
artikel
|
| 513 |
PMH12 PHARMACOECONOMIC ANALYSIS OF ANTIDEPRESSANTS IN BRAZIL
|
Machado, M
|
|
2006
|
9 |
6 |
p. A313-
1 p.
|
artikel
|
| 514 |
PMH14 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA: THE HUNGARIAN EXPERIENCE
|
Hansen, K
|
|
2006
|
9 |
6 |
p. A313-A314
nvt p.
|
artikel
|
| 515 |
PMH23 PREDICTING VIOLENT OFFENDING AMONG MENTALLY ILL IN A MULTINATIONAL SETTING–NAIVE BAYESIAN FUSION AND MODEL MERGING WITH P-COURSE
|
Soini, EJ
|
|
2006
|
9 |
6 |
p. A316-A317
nvt p.
|
artikel
|
| 516 |
PMH31 PREDICTORS FOR REHOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA
|
Gothe, H
|
|
2006
|
9 |
6 |
p. A319-
1 p.
|
artikel
|
| 517 |
PMH3 PREVALENCE AND COMORBIDITY BURDEN IN PATIENTS WITH BIPOLAR DISORDERS: CROSS-SECTIONAL ANALYSIS OF A HEALTH-PROVIDER ADMINISTRATIVE CLAIM DATABASE
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A310-
1 p.
|
artikel
|
| 518 |
PMH2 PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH BIPOLAR DISORDER:A CROSS-SECTIONAL ASSESSMENT OF A HEALTH MANAGEMENT ORGANIZATION IN SPAIN
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A309-A310
nvt p.
|
artikel
|
| 519 |
PMH42 QUALITY OF LIFE IN PATIENTS WITH BIPOLAR DISORDER IN 5 EUROPEAN COUNTRIES
|
Leeuwenkamp, O
|
|
2006
|
9 |
6 |
p. A322-
1 p.
|
artikel
|
| 520 |
PMH11 RATIONAL CHOICE OF TREATMENT STRATEGY IN MODERATE TO SEVERE ALZHEIMER'S DISEASE PATIENTS LIVING IN CANADA
|
Gagnon, M
|
|
2006
|
9 |
6 |
p. A312-A313
nvt p.
|
artikel
|
| 521 |
PMH35 REDUCTION IN SUICIDAL IDEATION AND VIOLENT BEHAVIOUR AFTER SIX MONTHS OF TREATMENT WITH LONG ACTING RISPERIDONE IN PATIENTS ENROLLED IN THE ELECTRONIC SCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (E-STAR)
|
Hustig, H
|
|
2006
|
9 |
6 |
p. A320-
1 p.
|
artikel
|
| 522 |
PMH22 REHOSPITALIZATION RATES IN SCHIZOPHRENIA: COMPREHENSIVE LITERATURE REVIEW
|
Rabinowitz, J
|
|
2006
|
9 |
6 |
p. A316-
1 p.
|
artikel
|
| 523 |
PMH26 RESOURCE USE AMONG PATIENTS WITH SCHIZOPHRENIA IN 5 EUROPEAN COUNTRIES
|
Leeuwenkamp, O
|
|
2006
|
9 |
6 |
p. A317-A318
nvt p.
|
artikel
|
| 524 |
PMH36 SIX-MONTH FOLLOW-UP FROM THE ELECTRONICSCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (ESTAR) OF PATIENTS IN SPAIN WHO WERE INITIATED TO RISPERIDONE LONG-ACTING INJECTION (RLAI)
|
Olivares, J
|
|
2006
|
9 |
6 |
p. A320-A321
nvt p.
|
artikel
|
| 525 |
PMH33 STRUCTURAL EQUATION MODELLING OF SCHIZOPHRENIA EARLY RETIREMENT IN GERMANY
|
Clouth, J
|
|
2006
|
9 |
6 |
p. A319-A320
nvt p.
|
artikel
|
| 526 |
PMH28 THE MANAGEMENT OF SCHIZOPHRENIA THROUGH CLINICAL PATHWAYS
|
Panella, M
|
|
2006
|
9 |
6 |
p. A318-
1 p.
|
artikel
|
| 527 |
PMH44 TRAJECTORIES OF PATIENT AND CLINICIAN REPORTED ANTIPSYCHOTIC COMPLIANCE IN THE SOHO STUDY AND THEIR CAUSES AND CONSEQUENCES
|
Croudace, TJ
|
|
2006
|
9 |
6 |
p. A323-
1 p.
|
artikel
|
| 528 |
PMH20 TREATMENT PATHWAYS AND COST ASSESSMENT OF SCHIZOPHRENIA IN GREECE: A PRIMARY ANALYSIS
|
Aggelopoulos, E
|
|
2006
|
9 |
6 |
p. A315-A316
nvt p.
|
artikel
|
| 529 |
PMH39 USE OF VERBALLY ADMINISTERED AND VERBALLY ORIENTING SCALES TO IMPROVE DATA COLLECTION
|
Wood, A
|
|
2006
|
9 |
6 |
p. A321-A322
nvt p.
|
artikel
|
| 530 |
PND10 A FUNCTIONAL ANALYSIS OF THE RELATIONSHIP BETWEEN AGE AND MIGRAINE IN THE UNITED STATES OF AMERICA
|
Victor, TW
|
|
2006
|
9 |
6 |
p. A376-A377
nvt p.
|
artikel
|
| 531 |
PND12 A LITERATURE REVIEW OF PATIENT-REPORTED OUTOMES (PROS), NEUROPSYCHOLOGICAL AND COGNITIVE INSTRUMENTS IN PARKINSON'S DISEASE
|
Staniek, V
|
|
2006
|
9 |
6 |
p. A377-
1 p.
|
artikel
|
| 532 |
PND3 COST-EFFECTIVENESS ANALYSIS OF ADD-ON THERAPY IN PARTIAL REFRACTORY EPILEPSY IN MEXICO
|
Constantino-Casas, P
|
|
2006
|
9 |
6 |
p. A374-A375
nvt p.
|
artikel
|
| 533 |
PND8 COST-EFFECTIVENESS OF TREATING RESTLESS LEGS PATIENTS WITH PRAMIPEXOLE COMPARED TO NO TREATMENT IN SWEDEN
|
Lees, M
|
|
2006
|
9 |
6 |
p. A376-
1 p.
|
artikel
|
| 534 |
PND9 COST UTILITY ANALYSIS OF LEVODOPA-CARBIDOPA VS LEVODOPA-CARBIDOPA-ENTACAPONE IN PARKINSON DISEASE IN MEXICO
|
Garcia-Contreras, F
|
|
2006
|
9 |
6 |
p. A376-
1 p.
|
artikel
|
| 535 |
PND2 ESTIMATING THE BUDGET IMPACT OF LEVETIRACETAM AS ADJUNCTIVE THERAPY IN CHILDREN WITH REFRACTORY PARTIAL ONSET SEIZURE IN THE UK
|
Heaney, D
|
|
2006
|
9 |
6 |
p. A374-
1 p.
|
artikel
|
| 536 |
PND1 META-ANALYSIS OF THE EFFICACY AND TOLERABILITY OF PRAMIPEXOLE AND ROPINIROLE IN RESTLESS LEGS SYNDROME (RLS)
|
Quilici, S
|
|
2006
|
9 |
6 |
p. A374-
1 p.
|
artikel
|
| 537 |
PND11 MODELING LONG-TERM “REAL WORLD” OUTCOMES OF DISEASE-MODIFYING THERAPY IN RELAPSING-REMITTING ONSET MULTIPLE SCLEROSIS
|
Skedgel, C
|
|
2006
|
9 |
6 |
p. A377-
1 p.
|
artikel
|
| 538 |
PND7 PREDICTORS OF HEALTH CARE AND NON-HEALTH COSTS IN PATIENTS WITH REFRACTORY EPILEPSY IN SPAIN: FINDINGS FROM THE LINCE STUDY
|
Rejas, J
|
|
2006
|
9 |
6 |
p. A375-A376
nvt p.
|
artikel
|
| 539 |
PND4 PREGABALIN VS GABAPENTIN IN THE TREATMENT OF NEUROPATHIC PAIN IN ITALY: A COST-EFFECTIVENESS ANALYSIS
|
Pradelli, L
|
|
2006
|
9 |
6 |
p. A375-
1 p.
|
artikel
|
| 540 |
PND13 PSICOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) IN PATIENTS WITH REFRACTORY EPILEPSY
|
Ruíz, MA
|
|
2006
|
9 |
6 |
p. A377-A378
nvt p.
|
artikel
|
| 541 |
PND15 RELAPSING-REMITTING MULTIPLE SCLEROSIS (RR-MS) PATIENTS' VALUATION OF MS TREATMENT BENEFITS
|
Narewska, J
|
|
2006
|
9 |
6 |
p. A378-
1 p.
|
artikel
|
| 542 |
PND6 RETROSPECTIVE EVALUTION OF THE DOSES OF BOTOX AND DYSPORT IN THE MANAGEMENT OF DYSTONIA—A COST MINIMISATION ANALYSIS
|
Jenkins, D
|
|
2006
|
9 |
6 |
p. A375-
1 p.
|
artikel
|
| 543 |
PND5 TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COSTEFFECTIVE TREATMENT STRATEGY IN FINLAND?
|
Armand, C
|
|
2006
|
9 |
6 |
p. A375-
1 p.
|
artikel
|
| 544 |
PND14 TREATMENT OF NEUROPATHIC PAIN IN MULTIPLE SCLEROSIS: A POPULATION BASED WILLINGNESS-TO-PAY ANALYSIS
|
Iskedjian, M
|
|
2006
|
9 |
6 |
p. A378-
1 p.
|
artikel
|
| 545 |
POB5 A MODELLED COST-EFFECTIVENESS EVALUATION OF SIBUTRAMINE THERAPY IN A HIGH RISK OBESE POPULATION
|
Walters, N
|
|
2006
|
9 |
6 |
p. A325-A326
nvt p.
|
artikel
|
| 546 |
POB1 ASSESSMENT OF THE CLINICAL RISK FACTORS FOR METABOLIC SYNDROME IN A NATIONAL PRIMARY CARE ELECTRONIC HEALTH RECORD (EHR) DATABASE
|
Brixner, D
|
|
2006
|
9 |
6 |
p. A324-
1 p.
|
artikel
|
| 547 |
POB3 BURDEN OF ILLNESS OF ABDOMINAL OBESITY: A RETROSPECTIVE CHART REVIEW
|
Strens, D
|
|
2006
|
9 |
6 |
p. A325-
1 p.
|
artikel
|
| 548 |
POB2 COST-EFFECTIVENESS OF TREATING CARDIOMETABOLIC PATIENTS WITH RIMONABANT (ACOMPLIA®) IN A DANISH SETTING
|
Knudsen, MS
|
|
2006
|
9 |
6 |
p. A324-A325
nvt p.
|
artikel
|
| 549 |
POB9 DEVELOPMENT OF A NEW QUESTIONNAIRE FOR IDENTIFING PREDICTIVE FACTORS INFLUENCING WEIGHT LOSS THERAPIES
|
Ruíz, MA
|
|
2006
|
9 |
6 |
p. A327-
1 p.
|
artikel
|
| 550 |
POB6 IN EUROPE, HOW REPRESENTATIVE ARE OVERWEIGHT/OBESE SUBJECTS RECRUITED VIA THE INTERNET?
|
Zhou, X
|
|
2006
|
9 |
6 |
p. A326-
1 p.
|
artikel
|
| 551 |
POB10 RIMONABANT IMPROVES HEALTH-RELATED QUALITY OF LIFE IN OVERWEIGHT/OBESE PATIENTS WITH TYPE 2 DIABETES: RIO-DIABETES STUDY
|
Kolotkin, RL
|
|
2006
|
9 |
6 |
p. A327-
1 p.
|
artikel
|
| 552 |
POB8 THE IMPACT OF BODY WEIGHT ON UTILITY SCORES IN PATIENTS WITH TYPE 2 DIABETES
|
Dennett, SL
|
|
2006
|
9 |
6 |
p. A326-A327
nvt p.
|
artikel
|
| 553 |
POB7 THE RELATIONSHIP BETWEEN WEIGHT CHANGES AND RELATED CHANGES IN HEALTH-RELATED UTILITY: EVIDENCE OF CAUSE AND AFFECT
|
Woehl, A
|
|
2006
|
9 |
6 |
p. A326-
1 p.
|
artikel
|
| 554 |
POB4 USING CLAIMS DATA TO UNDERSTAND THE COSTS OF DIFFERENT HEALTH STATES FOR PATIENTS WITH CARDIOMETABOLIC RISK
|
Mangiapane, S
|
|
2006
|
9 |
6 |
p. A325-
1 p.
|
artikel
|
| 555 |
POS5 AN ECONOMIC EVALUATION OF ZOLEDRONIC ACID TREATMENT IN PAGET'S DISEASE OF BONE IN THE HUNGARIAN HEALTH CARE SETTING
|
Kosa, J
|
|
2006
|
9 |
6 |
p. A380-
1 p.
|
artikel
|
| 556 |
POS17 BASELINE CHARACTERISTICS OF FRENCH POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)
|
Rajzbaum, G
|
|
2006
|
9 |
6 |
p. A383-
1 p.
|
artikel
|
| 557 |
POS15 CHANGES IN THE HEALTH STATUS AFTER FEMORAL NECK FRACTURE MEASURED BY EQ-5D
|
Sebestyén, A
|
|
2006
|
9 |
6 |
p. A383-
1 p.
|
artikel
|
| 558 |
POS4 COMPARING THE COST-EFFECTIVENESS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN GERMANY, FRANCE, AND UK
|
Chhabra, A
|
|
2006
|
9 |
6 |
p. A379-A380
nvt p.
|
artikel
|
| 559 |
POS9 COMPARISON OF THE BURDEN OF ILLNESS OF DISPLACED AND UNDISPLACED FEMORAL NECK FRACTURE AFTER REDUCTION INTERNAL FIXATION
|
Sebestyén, A
|
|
2006
|
9 |
6 |
p. A381-
1 p.
|
artikel
|
| 560 |
POS7 COST-EFFECTIVENESS OF RISEDRONATE VS. GENERIC ALENDRONATE: CONSIDERATION OF CALCIUM SUPPLEMENTS
|
Moehrke, W
|
|
2006
|
9 |
6 |
p. A380-
1 p.
|
artikel
|
| 561 |
POS6 ECONOMIC ANALYSIS: IBANDRONATE (BONVIVA®) IV INJECTION FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS (PMO) IN THE UK
|
Cowell, W
|
|
2006
|
9 |
6 |
p. A380-
1 p.
|
artikel
|
| 562 |
POS1 EFFECT OF COMORBIDITIES ON THE EARLY MORTALITY AFTER FEMORAL NECK FRACTURE IN ELDERLY IN HUNGARY
|
Sebestyén, A
|
|
2006
|
9 |
6 |
p. A378-A379
nvt p.
|
artikel
|
| 563 |
POS11 EVOLUTION OF THE CONSUMPTION OF BISPHOSPHONATES AND RALOXIFENE FINANCED BY THE SPANISH NATIONAL HEALTH SYSTEM FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
|
Gaspar, MD
|
|
2006
|
9 |
6 |
p. A381-A382
nvt p.
|
artikel
|
| 564 |
POS3 KAPLAN-MEIER SURVIVAL ANALYSIS OF PATIENTS WITH MEDIAL AND LATERAL FEMORAL NECK FRACTURE OVER 60
|
Sebestyén, A
|
|
2006
|
9 |
6 |
p. A379-
1 p.
|
artikel
|
| 565 |
POS16 LONG TERM QUALITY OF LIFE RELATED TO OSTEOPOROTIC FRACTURES; 13–18 MONTHS AFTER FRACTURE
|
Ström, O
|
|
2006
|
9 |
6 |
p. A383-
1 p.
|
artikel
|
| 566 |
POS2 LOSS OF TREATMENT BENEFIT DUE TO LOW COMPLIANCE WITH BISPHOSPHONATE THERAPY
|
Penning-van Beest, FJA
|
|
2006
|
9 |
6 |
p. A379-
1 p.
|
artikel
|
| 567 |
POS10 OSTEOPOROSIS RELATED HEALTH CARE UTILISATION IN HUNGARY BY THE NATIONWIDE HEALTH INSURANCE DATABASE
|
Gulácsi, L
|
|
2006
|
9 |
6 |
p. A381-
1 p.
|
artikel
|
| 568 |
POS14 QUALITY OF LIFE ACCORDING TO EQ-5D AFTER OSTEOPOROTIC HIP FRACTURE IN POLAND
|
Golicki, D
|
|
2006
|
9 |
6 |
p. A382-A383
nvt p.
|
artikel
|
| 569 |
POS12 THE DIFFUSION OF NEW DRUG IN TAIWAN MEDICAL CARE UNDER NATIONAL HEALTH INSURANCE: THE CASE OF COX2
|
Tsai, YW
|
|
2006
|
9 |
6 |
p. A382-
1 p.
|
artikel
|
| 570 |
POS13 THE ESTIMATION OF COST–EFFECTIVENESS THRESHOLDS PRIOR TO THE START OF LARGE CLINICAL STUDIES
|
Van Staa, TP
|
|
2006
|
9 |
6 |
p. A382-
1 p.
|
artikel
|
| 571 |
POS8 THE SOCIETAL BURDEN OF OSTEOPOROSIS
|
Borgström, F
|
|
2006
|
9 |
6 |
p. A381-
1 p.
|
artikel
|
| 572 |
PPN4 ECONOMIC EVALUATION COMPARING BMP-2 (INDUCTOSTM) VERSUS CURRENT TREATMENT IN CHRONIC LOWER BACK PAIN IN THE SPANISH SETTING
|
Serrano, D
|
|
2006
|
9 |
6 |
p. A328-A329
nvt p.
|
artikel
|
| 573 |
PPN1 INTRAVENOUS PARACETAMOL IN POSTOPERATIVE PAIN MANAGEMENT–SYSTEMATIC REVIEW AND META ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
|
Golicki, D
|
|
2006
|
9 |
6 |
p. A327-A328
nvt p.
|
artikel
|
| 574 |
PPN2 META-ANALYSIS OF DULOXETINE VS. PREGABALIN AND GABAPENTIN IN THE TREATMENT OF PERIPHERAL DIABETIC NEUROPATHIC PAIN
|
Quilici, S
|
|
2006
|
9 |
6 |
p. A328-
1 p.
|
artikel
|
| 575 |
PPN3 SAFETY OF INTRAVENOUS FORMULATIONS OF METAMIZOLE, KETOPROFEN AND PARACETAMOL—ANALYSIS OF DATA FROM WHO PROGRAMME FOR INTERNATIONAL DRUG MONITORING
|
Golicki, D
|
|
2006
|
9 |
6 |
p. A328-
1 p.
|
artikel
|
| 576 |
PR2 ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING THE SPANISH VERSION OF THE SF-36. DATA OF VALIDITY OF THE SF-6D VS EQ-5D IN SPAIN
|
Rebollo, P
|
|
2006
|
9 |
6 |
p. A195-
1 p.
|
artikel
|
| 577 |
PR1 HEALTH RELATED QUALITY OF LIFE IN DIFFERENT STATES OF BREAST CANCER
|
Lidgren, M
|
|
2006
|
9 |
6 |
p. A195-
1 p.
|
artikel
|
| 578 |
PR3 LOW ADHERENCE WITH GASTROPROTECTIVE AGENTS WHEN CO-PRESCRIBED WITH NSNSAIDS ASSOCIATED WITH INCREASING RISK OF GI-RELATED HOSPITALISATION
|
Koncz, T
|
|
2006
|
9 |
6 |
p. A195-
1 p.
|
artikel
|
| 579 |
PR4 PREFERENCES OF PEOPLE WITH DIABETES FOR INHALED AND INJECTABLE INSULIN REGIMENS
|
Chancellor, J
|
|
2006
|
9 |
6 |
p. A195-A196
nvt p.
|
artikel
|
| 580 |
PRS9 CLINICAL PRACTICE VS GOLD RECOMMENDATIONS IN THE MANAGEMENT OF COPD PATIENTS: AN ECONOMIC ANALYSIS OF THE LACK OF ADHERENCE TO GUIDELINES
|
Brosa, M
|
|
2006
|
9 |
6 |
p. A262-A263
nvt p.
|
artikel
|
| 581 |
PRS6 CONSEQUENCES FOR DRG-IMPLEMENTATION IN GERMANY: EFFECT ON DIRECT COSTS OF IN-PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA FROM HOSPITAL'S PERSPECTIVE
|
De Zeeuw, J
|
|
2006
|
9 |
6 |
p. A261-A262
nvt p.
|
artikel
|
| 582 |
PRS3 COST-EFFECTIVENESS OF ROFLUMILAST IN THE UK:A 1-YEAR STUDY IN PATIENTS WITH SEVERE TO VERY SEVERE COPD
|
Van Nooten, F
|
|
2006
|
9 |
6 |
p. A260-A261
nvt p.
|
artikel
|
| 583 |
PRS5 COSTS OF COPD EXACERBATIONS IN POLAND (RESULTS OF THE PILOT STUDY)
|
Jahnz-Rozyk, KM
|
|
2006
|
9 |
6 |
p. A261-
1 p.
|
artikel
|
| 584 |
PRS2 EFFECT OF DRG IMPLEMENTATION IN GERMANY–ANALYSIS OF LENGTH OF HOSPITAL STAY OF IN-PATIENTS SUFFERING FROM COMMUNITY-ACQUIRED PNEUMONIA
|
De Zeeuw, J
|
|
2006
|
9 |
6 |
p. A260-
1 p.
|
artikel
|
| 585 |
PRS19 EPIDEMIOLOGICAL STUDY TO INVESTIGATE PATIENTS' VIEWS ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
|
Georgatou, N
|
|
2006
|
9 |
6 |
p. A266-
1 p.
|
artikel
|
| 586 |
PRS7 ESTIMATION OF MORBIDITY, RESOURCE UTILIZATION AND COST IN SUBJECTS TREATED WITH TIOTROPIUM BROMIDE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A SPANISH POPULATION SETTING
|
Sicras, A
|
|
2006
|
9 |
6 |
p. A262-
1 p.
|
artikel
|
| 587 |
PRS12 EXPECTED VALUE OF PERFECT INFORMATION: A PRACTICAL EXAMPLE OF REDUCING DECISION UNCERTAINTY BY CONDUCTING ADDITIONAL RESEARCH
|
Oostenbrink, JB
|
|
2006
|
9 |
6 |
p. A263-A264
nvt p.
|
artikel
|
| 588 |
PRS15 IMPROVING THE PERSISTENCE OF PATIENTS UNDERGOING SUBLINGUAL IMMUNOTHERAPY: SCORING AND VALIDATION OF A PATIENT-MANAGEMENT TOOL
|
Arnould, B
|
|
2006
|
9 |
6 |
p. A264-A265
nvt p.
|
artikel
|
| 589 |
PRS18 MEASURING DISEASE-SPECIFIC UTILITIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTH- AND EXACERBATION PROFILES
|
Rutten- van Molken, M
|
|
2006
|
9 |
6 |
p. A265-A266
nvt p.
|
artikel
|
| 590 |
PRS16 MEASURING THE IMPACT OF COPD ON PATIIENTS' LIVES IN AN INTERNATIONAL STUDY
|
Mear, I
|
|
2006
|
9 |
6 |
p. A265-
1 p.
|
artikel
|
| 591 |
PRS14 PERSISTENCE WITH TIOTROPIUM: A COMPARISON WITH ESTABLISHED MEDICATIONS FOR COPD
|
Koerselman, J
|
|
2006
|
9 |
6 |
p. A264-
1 p.
|
artikel
|
| 592 |
PRS1 PREVALENCE AND TREATMENT OF COPD IN GERMANY
|
Höer, A
|
|
2006
|
9 |
6 |
p. A260-
1 p.
|
artikel
|
| 593 |
PRS10 PREVALENCE OF PULMONARY HYPERTENSION IN GERMANY–ESTIMATIONS BASED ON A TOP-DOWN APPROACH
|
Ehlken, B
|
|
2006
|
9 |
6 |
p. A263-
1 p.
|
artikel
|
| 594 |
PRS8 RISK OF HOSPITALIZATIONS AND/OR EMERGENCY DEPARTMENT VISITS FOR MEDICAID PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): COMPARISON OF CONTROLLERS
|
Rascati, KL
|
|
2006
|
9 |
6 |
p. A262-
1 p.
|
artikel
|
| 595 |
PRS4 THE COST-EFFECTIVENESS OF DRUG THERAPY IN COMMUNITY-ACQUIRED PNEUMONIA AND THE IMPACT OF ANTIMICROBIAL RESISTANCE IN GERMANY
|
Martin, M
|
|
2006
|
9 |
6 |
p. A261-
1 p.
|
artikel
|
| 596 |
PRS11 THE TREATMENT OF RESPIRATORY DISEASES AND HEALTH CARE BUDGET IMPACT WITHIN SLOVAKIA
|
Tesar, T
|
|
2006
|
9 |
6 |
p. A263-
1 p.
|
artikel
|
| 597 |
PRS13 USING PATIENT DESCRIPTORS TO DEVELOP A PRO MEASUREMENT STRATEGY FOR CLINICAL TRIALS: EVALUATING THE COPD PATIENT'S EXPERIENCE OF DYSPNEA
|
Martin, M
|
|
2006
|
9 |
6 |
p. A264-
1 p.
|
artikel
|
| 598 |
PRS17 VALIDATION OF THE COPD SEVERITY SCORE FOR USE IN THE SPANISH PRIMARY HEALTH CARE SYSTEM, THE NEREA STUDY: PRELIMINARY RESULTS
|
Ferrer, M
|
|
2006
|
9 |
6 |
p. A265-
1 p.
|
artikel
|
| 599 |
PSK3 A COST-EFFECTIVENESS ANALYSIS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS
|
Roberts, G
|
|
2006
|
9 |
6 |
p. A267-
1 p.
|
artikel
|
| 600 |
PSK6 BELGIAN DRUG UTILISATION STUDY OF ELIDEL® IN ROUTINE PRACTICE IN ATOPIC DERMATITIS
|
Lecomte, P
|
|
2006
|
9 |
6 |
p. A268-
1 p.
|
artikel
|
| 601 |
PSK11 CARE GIVERS' WILLINGNESS TO PAY FOR DIFFERENT CHARACTERISTICS OF THE ATOPIC DERMATITIS TREATMENT
|
Monzini, MS
|
|
2006
|
9 |
6 |
p. A269-A270
nvt p.
|
artikel
|
| 602 |
PSK7 CONVERGENT VALIDITY AND SENSITIVITY TO CHANGE OF GENERIC AND DISEASE-SPECIFIC INSTRUMENTS USED IN CHILDREN WITH ATOPIC DERMATITIS
|
Scalone, L
|
|
2006
|
9 |
6 |
p. A268-
1 p.
|
artikel
|
| 603 |
PSK8 CONVERGENT VALIDITY AND SENSITIVITY TO CHANGE OF THE GENERIC INSTRUMENT EQ-5D AND THE DISEASESPECIFIC DLQI IN ATOPIC DERMATITIS
|
Scalone, L
|
|
2006
|
9 |
6 |
p. A268-A269
nvt p.
|
artikel
|
| 604 |
PSK4 COST-EFFECTIVENESS OF TOPICAL CALCIPOTRIOL/BETAMETHASONE DIPROPIONATE TWOCOMPOUND PRODUCT IN A SCOTTISH CARE MODEL
|
Morton, CA
|
|
2006
|
9 |
6 |
p. A267-
1 p.
|
artikel
|
| 605 |
PSK5 COST OF ATOPIC DERMATIS IN ADULTS: THE CODA STUDY
|
De Portu, S
|
|
2006
|
9 |
6 |
p. A267-A268
nvt p.
|
artikel
|
| 606 |
PSK1 EFFICACY OF BIOLOGICAL THERAPIES IN THE TREATMENT OF PSORIASIS: A META-ANALYSIS
|
Roberts, G
|
|
2006
|
9 |
6 |
p. A266-
1 p.
|
artikel
|
| 607 |
PSK2 MEDICATION ADHERENCE AND HEALTH CARE COSTS ASSOCIATED WITH BIOLOGICS IN MEDICAID-ENROLLED PATIENTS WITH PSORIASIS
|
Balkrishnan, R
|
|
2006
|
9 |
6 |
p. A266-A267
nvt p.
|
artikel
|
| 608 |
PSK10 OVERCOMING DIFFERENTIAL ITEM FUNCTIONING ASSOCIATED WITH MEASURING PATIENT REPORTED OUTCOMES IN MULTINATIONAL CLINICAL TRIALS
|
McKenna, SP
|
|
2006
|
9 |
6 |
p. A269-
1 p.
|
artikel
|
| 609 |
PSK9 QUALITY OF LIFE OF ADULT PATIENTS WITH ATOPIC DERMATITIS: THE CODA STUDY
|
Scalone, L
|
|
2006
|
9 |
6 |
p. A269-
1 p.
|
artikel
|
| 610 |
PSM2 COST-UTILITY ANALYSIS FOR SMOKING CESSATION THERAPY IN JAPAN
|
Igarashi, A
|
|
2006
|
9 |
6 |
p. A384-
1 p.
|
artikel
|
| 611 |
PSM1 THE HIGH COST OF CIGARETTE SMOKING IN GERMANY IN 2003
|
Neubauer, S
|
|
2006
|
9 |
6 |
p. A384-
1 p.
|
artikel
|
| 612 |
PST1 BUDGETARY IMPACT ANALYSIS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE: A US HEALTH PLAN PERSPECTIVE
|
Earnshaw, SR
|
|
2006
|
9 |
6 |
p. A329-
1 p.
|
artikel
|
| 613 |
PST4 DIFFERENCES IN DISCHARGE LOCATION FOR PATIENTS WITH MULTIPLE ISCHEMIC STROKE ADMISSIONS: IMPLICATIONS FOR POST-ACUTE CARE COSTS
|
O'Brien, JA
|
|
2006
|
9 |
6 |
p. A330-
1 p.
|
artikel
|
| 614 |
PST3 RESOURCE UTILIZATION AND COSTS OF STROKES IN A THIRD LEVEL HOSPITAL IN MÉXICO
|
Carbajal, A
|
|
2006
|
9 |
6 |
p. A329-A330
nvt p.
|
artikel
|
| 615 |
PST2 STROKE PATIENT RESOURCE USE AND CAREGIVER BURDEN OUTCOMES BY SEVERITY (RECOVERY) STUDY: METHODS AND PRELIMINARY GERMAN RESULTS
|
Payne, K
|
|
2006
|
9 |
6 |
p. A329-
1 p.
|
artikel
|
| 616 |
PST5 THE WEAKNESS OF TEAMWORK BETWEEN NURSES AND PHYSIOTHERAPISTS IN CARING FOR STROKE PATIENTS IN HUNGARY
|
Betlehem, J
|
|
2006
|
9 |
6 |
p. A330-
1 p.
|
artikel
|
| 617 |
PST6 UTILITY LOSS AND INDIRECT COSTS AFTER STROKE IN SWEDEN
|
Lindgren, P
|
|
2006
|
9 |
6 |
p. A330-
1 p.
|
artikel
|
| 618 |
PSU1 A COST-EFFECTIVENESS EVALUATION OF VACUUM ASSISTED CLOSURE (V.A.C.THERAPY) TREATMENT FOR DEHISCED CHEST WOUND PATIENTS
|
Song, D
|
|
2006
|
9 |
6 |
p. A330-A331
nvt p.
|
artikel
|
| 619 |
PSU3 DEMOGRAPHIC PREDICTORS OF RESOURCE UTILIZATION AND COSTS OF SOLID ORGAN TRANSPLANTATION IN BRITISH COLUMBIA, CANADA
|
Levy, AR
|
|
2006
|
9 |
6 |
p. A331-
1 p.
|
artikel
|
| 620 |
PSU2 ECONOMIC EVALUATION COMPARING FROM HOME TO OPERATION AND CONVENTIONAL PROCESS OF LAPAROSCOPIC CHOLECYSTECTOMY: PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
|
Soini, EJ
|
|
2006
|
9 |
6 |
p. A331-
1 p.
|
artikel
|
| 621 |
PSU4 VENTRAL, UMBILICAL, AND INGUINAL HERNIA: REVIEW OF THE CURRENT LITERATURE
|
De Jonge, P
|
|
2006
|
9 |
6 |
p. A332-
1 p.
|
artikel
|
| 622 |
PUK10 A COMPARATIVE STUDY OF THE ECONOMIC BURDEN OF OVERACTIVE BLADDER AND URINARY URGE INCONTINENCE ACROSS 6 WESTERN COUNTRIES
|
Reeves, P
|
|
2006
|
9 |
6 |
p. A387-
1 p.
|
artikel
|
| 623 |
PUK14 A COST-UTILITY ANALYSIS IN A UK SETTING OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE
|
Mealing, SJ
|
|
2006
|
9 |
6 |
p. A388-A389
nvt p.
|
artikel
|
| 624 |
PUK18 A MULTICENTRE STUDY OF RENAL TRANSPLANT PATIENTS USING THE SF-36 AND THE END STAGE RENAL DISEASE SYMPTOM CHECK-LIST (ESRD-SCL)
|
Ortega, T
|
|
2006
|
9 |
6 |
p. A390-
1 p.
|
artikel
|
| 625 |
PUK4 AN ECONOMIC EVALUATION OF DE NOVO RENAL TRANSPLANT RECIPIENTS USING BRANDED (B-CSA) VS. NON-BRANDED CYCLOSPORINE MODIFIED (NB-CSA)
|
Helderman, JH
|
|
2006
|
9 |
6 |
p. A385-
1 p.
|
artikel
|
| 626 |
PUK3 BUDGET IMPACT ANALYSIS OF INCLUDING RENAL REPLACEMENT THERAPY IN THE BENEFIT PACKAGE OF UNIVERSAL COVERAGE IN THAILAND
|
Kasemsup, V
|
|
2006
|
9 |
6 |
p. A385-
1 p.
|
artikel
|
| 627 |
PUK22 COMPARISON OF THE PRO ENDPOINTS FOUND IN LABELING CLAIMES OF URINARY INCONTINENCE DRUGS WITH THOSE RECOMMENDED BY THE CORRESPONDING EMEA NOTE FOR GUIDANCE
|
Caron, M
|
|
2006
|
9 |
6 |
p. A391-
1 p.
|
artikel
|
| 628 |
PUK16 COST-EFFECTIVENESS ANALYSIS OF SOLIFENACIN FLEXIBLE DOSING IN PATIENTS WITH OVERACTIVE BLADDER SYMPTOMS IN FOUR NORDIC COUNTRIES
|
Milsom, I
|
|
2006
|
9 |
6 |
p. A389-
1 p.
|
artikel
|
| 629 |
PUK6 COST-EFFECTIVENESS OF TREATMENT WITH EPOIETIN ALPHA FOR PATIENTS WITH ANAEMIA DUE TO RENAL FAILURE—THE CASE OF SWEDEN
|
Glenngård, AH
|
|
2006
|
9 |
6 |
p. A386-
1 p.
|
artikel
|
| 630 |
PUK8 COST-EFFICACY OF FINASTERIDE, DOXAZOSIN AND THE COMBINATION OF BOTH IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN FRANCE BASED ON THE MTOPS STUDY
|
Lafuma, A
|
|
2006
|
9 |
6 |
p. A386-A387
nvt p.
|
artikel
|
| 631 |
PUK9 COST OF ILLNESS IN ITALIAN WOMEN WITH LUTS FOLLOWED AT UROLOGY CENTRES: THE FLOW STUDY
|
Sgarbi, S
|
|
2006
|
9 |
6 |
p. A387-
1 p.
|
artikel
|
| 632 |
PUK5 COSTS AND COST-EFFECTIVENESS OF EPOETIN IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY DURING THE PREDIALYSIS PERIOD IN POLAND
|
Niewada, M
|
|
2006
|
9 |
6 |
p. A385-A386
nvt p.
|
artikel
|
| 633 |
PUK11 COST UTILITY ANALYSIS OF ERYTHROPOIETIN THERAPY IN THE MINISTRY OF HEALTH DIALYSIS PROGRAMME
|
Aryani Md. Yusof, F
|
|
2006
|
9 |
6 |
p. A387-A388
nvt p.
|
artikel
|
| 634 |
PUK12 DECISION MODEL OF RESOURCE (TIME) SAVINGS GENERATED BY EXTENDED DOSING OF ERYTHROPOIESIS STIMULATING PROTEIN (ESP) FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS
|
Barlev, A
|
|
2006
|
9 |
6 |
p. A388-
1 p.
|
artikel
|
| 635 |
PUK7 ECONOMIC EVALUATION OF TRANSURETHRAL NEEDLE ABLATION (PROSTIVA®) VS.TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) IN BENIGN PROSTATIC HYPERPLASIA (BPH) IN THE SPANISH SETTING
|
Serrano, D
|
|
2006
|
9 |
6 |
p. A386-
1 p.
|
artikel
|
| 636 |
PUK1 FACTORS ASSOCIATED WITH OVERACTIVE BLADDER IN MEN AND WOMEN: RESULTS FROM THE EPIC STUDY
|
Irwin, DE
|
|
2006
|
9 |
6 |
p. A384-
1 p.
|
artikel
|
| 637 |
PUK23 IMPACT OF OVERACTIVE BLADDER ON FREQUENCY OF SEXUAL ACTIVITY AND SEXUAL SATISFACTION IN WOMEN: RESULTS FROM THE EPIC STUDY
|
Irwin, DE
|
|
2006
|
9 |
6 |
p. A391-
1 p.
|
artikel
|
| 638 |
PUK24 LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q), OVERACTIVE BLADDER SHORT FORM QUESTIONNAIRE (OAB-Q SF), AND OAB ASSESSMENT TOOL (OAB-V8) IN 4 LANGUAGES
|
Reilly, K
|
|
2006
|
9 |
6 |
p. A391-A392
nvt p.
|
artikel
|
| 639 |
PUK26 LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER SATISFACTION QUESTIONNAIRE (OAB-S) IN 13 LANGUAGES
|
Reilly, K
|
|
2006
|
9 |
6 |
p. A392-
1 p.
|
artikel
|
| 640 |
PUK25 LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF BLADDER CONDITION QUESTIONNAIRE (PPBC) IN 10 LANGUAGES
|
Reilly, K
|
|
2006
|
9 |
6 |
p. A392-
1 p.
|
artikel
|
| 641 |
PUK2 LINKING CNI REGIMEN ADHERENCE TO HOSPITAL DAYS AND HEALTH CARE COSTS
|
Legorreta, AP
|
|
2006
|
9 |
6 |
p. A385-
1 p.
|
artikel
|
| 642 |
PUK15 MODELLING COST-EFFECTIVENESS USING A DYNAMIC PRICE PATH WITH GENERIC SUBSTITUTION SCENARIOS: COSTEFFECTIVENESS OF CINACALCET IN UK PATIENTS WITH END-STAGE RENAL DISEASE (ESRD) ON HEMODIALYSIS
|
Maetzel, A
|
|
2006
|
9 |
6 |
p. A389-
1 p.
|
artikel
|
| 643 |
PUK19 OPEN MULTICENTER STUDY OF HEALTH RE LATED QUALITY OF LIFE BEFORE AND AFTER SOLID ORGAN TRANSPLANTATION (KIDNEY, LIVER, HEART AND LUNG)
|
Ortega, T
|
|
2006
|
9 |
6 |
p. A390-
1 p.
|
artikel
|
| 644 |
PUK20 PATIENTS UNDER 65 YEARS OF AGE ON RENAL TRANSPLANT WAITING LISTS SHOW A WORSE PERCEIVED STATE OF HEALTH THAN OLDER ONES
|
Rebollo, P
|
|
2006
|
9 |
6 |
p. A390-
1 p.
|
artikel
|
| 645 |
PUK21 RESEARCH NETWORK ON TRANSPLANTATION: FEMALES ON THE WAITING LIST FOR RENAL TRANSPLANT SHOW A POORER PERCEIVED STATE OF HEALTH THAN DO MALES
|
Rebollo, P
|
|
2006
|
9 |
6 |
p. A390-A391
nvt p.
|
artikel
|
| 646 |
PUK27 RISK OF LEAKAGES IN DAILY ACTIVITIES, RE-WORKING THE CONCEPTUAL FRAMEWORK
|
Arnould, B
|
|
2006
|
9 |
6 |
p. A392-A393
nvt p.
|
artikel
|
| 647 |
PUK13 TRENDS IN MEDICATION PRESCRIPTION FOR ANEMIA MANAGEMENT OF CHRONIC KIDNEY DISEASE IN A NATIONALLY REPRESENTATIVE SAMPLE OF OUTPATIENT SETTINGS IN THE UNITED STATES
|
Rasu, RS
|
|
2006
|
9 |
6 |
p. A388-
1 p.
|
artikel
|
| 648 |
PUK17 USE OF SIMULATION TO CAPTURE THE MULTIFACTORIAL ASPECTS OF RENAL DISEASE
|
Migliaccio-Walle, K
|
|
2006
|
9 |
6 |
p. A389-A390
nvt p.
|
artikel
|
| 649 |
PUK28 VALIDATION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL FUNCTION QUESTIONNAIRE IN ITALIAN WOMEN. THE GYNAEFLOW STUDY
|
Simoni, L
|
|
2006
|
9 |
6 |
p. A393-
1 p.
|
artikel
|
| 650 |
RS1 CAN PHARMACEUTICAL INDUSTRY USE REPS TO PROVIDE MEDICAL PRACTICE GUIDELINES? (MIGRAINE AND ASTHMA)
|
Chaix-couturier, C
|
|
2006
|
9 |
6 |
p. A201-
1 p.
|
artikel
|
| 651 |
RS4 CLINICALLY IMPORTANT FACTORS CONTRIBUTING TO COSTS OF CARE DEFINED VIA ANALYSIS OF COMPREHSIVE PATIENT RECORDS
|
Palmu, PJ
|
|
2006
|
9 |
6 |
p. A202-
1 p.
|
artikel
|
| 652 |
RS3 THE COST-EFFECTIVENESS OF TIOTROPIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Akobundu, E
|
|
2006
|
9 |
6 |
p. A202-
1 p.
|
artikel
|
| 653 |
RS2 TREATMENT WITH INHALED CORTICOSTEROIDS IN ASTHMA TOO OFTEN DISCONTINUED
|
Breekveldt-Postma, NS
|
|
2006
|
9 |
6 |
p. A201-A202
nvt p.
|
artikel
|
| 654 |
SZ4 A CARER'S PERSPECTIVE ON THE VALUATION OF SCHIZOPHRENIA-RELATED HEALTH STATES USING THE ASSESSMENT OF QUALITY OF LIFE QUESTIONNAIRE AND THE EQ5D
|
Adams, J
|
|
2006
|
9 |
6 |
p. A197-
1 p.
|
artikel
|
| 655 |
SZ1 EFFECTIVENESS AND COSTS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA IN ROUTINE CARE
|
Stargardt, T
|
|
2006
|
9 |
6 |
p. A196-
1 p.
|
artikel
|
| 656 |
SZ3 PREDICTORS OF GAF CHANGES IN AUSTRALIANS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONGACTING INJECTION (RLAI): INTERIM RESULTS FROM THE E-STAR STUDY
|
Lambert, T
|
|
2006
|
9 |
6 |
p. A196-A197
nvt p.
|
artikel
|
| 657 |
SZ2 TREATMENT PERSISTENCE WITH DIFFERENT ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA
|
Ren, X
|
|
2006
|
9 |
6 |
p. A196-
1 p.
|
artikel
|
| 658 |
Too Much Ado about Propensity Score Models? Comparing Methods of Propensity Score Matching
|
Baser, Onur
|
|
2006
|
9 |
6 |
p. 377-385
9 p.
|
artikel
|
| 659 |
Too Much Ado about Propensity Score Models? Comparing Methods of Propensity Score Matching
|
Baser, Onur
|
|
2006
|
9 |
6 |
p. 377-385
|
artikel
|
| 660 |
Value in Health
|
|
|
2006
|
9 |
6 |
p. A411-A415
nvt p.
|
artikel
|
| 661 |
Value in Health
|
|
|
2006
|
9 |
6 |
p. A411-A415
|
artikel
|
Tijdschrift beschrijving